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ABSTRACT 
 
 
 Current research suggests resveratrol, a phytoalexin found predominately in grapes, may 
function as a chemopreventive and/or chemotherapeutic agent for various cancers, including 
colorectal cancer.  However, the underlying mechanism(s) involved in these activities remain 
elusive.  Thus, the objective of the studies discussed here sought to investigate the effect of 
resveratrol treatment on gene modulation in human colorectal cancer cells in order to identify 
and characterize novel molecular targets that contribute to the observed anticancer activities of 
resveratrol.  Here, we identify activating transcription factor 3 (ATF3) and early growth 
response-1 (Egr-1) as novel targets of resveratrol and provide data to elucidate the mechanism(s) 
of regulation and how each target contributes to the anticancer effect of resveratrol in colorectal 
cancer cells.  We demonstrate the involvement of resveratrol in ATF3 transcriptional regulation, 
which is facilitated by Egr-1 and Krüppel-like factor 4 interactions, and show that ATF3 
contributes, at least partially, to resveratrol-induced apoptosis (Chapter 3).  Moreover, we 
suggest that increased Egr-1 transcriptional activity by resveratrol requires posttranslational 
acetylation of Egr-1 in a SIRT1-independent manner.  This acetylation by resveratrol may 
contribute to Egr-1-mediated expression of the pro-apoptotic protein nonsteroidal anti-
inflammatory drug (NSAID)-activated gene-1 (NAG-1) induced by the phytoalexin (Chapter 4).  
Taken together, the work presented here provide (1) novel mechanisms by which resveratrol 
induces ATF3 and Egr-1 expression and (2) represent additional explanations for the anti-
tumorigenic/anti-carcinogenic effects of resveratrol in human colorectal cancer cells.         
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This chapter is revised based on the Baek SJ and Whitlock NC book chapter published by 
Springer Science+Business Media: 
 
Baek SJ and Whitlock NC. Molecular targets of resveratrol in carcinogenesis. In: 
Cho WCS, ed. Evidence-Based Anticancer Materia Medica. Dordrecht, Netherlands: 
Springer Science+Business Media; 2011: 313-340. 
 
My contributions to this work include: (1) gathering and reviewing the literature, (2) creating 
tables and figures, (3) drafting and revising the chapter, and (4) final approval of the 
published version.  SJB revised and approved the final version for publication. 
 
 
 
 
1.1. Abstract 
 Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess 
anti-tumorigenic and anti-inflammatory activity in several cancers.  However, the molecular 
mechanisms and/or targets underlying the anti-tumorigenic activity of this compound remain 
largely unknown.  As a potential signaling pathway modulator, resveratrol is shown to affect 
a multitude of signaling transduction pathways, and it is likely that this collective activity 
may play an important role in resveratrol-induced anti-tumorigenesis.  Therefore, the 
elucidation of molecular targets of resveratrol is necessary to understand how this compound 
is beneficial in anti-tumorigenic processes.  Studies to identify molecular makers have 
recently spawned increasing examination of possible targets of resveratrol as related to 
anticancer proteins.  These include, but are not limited to: (1) inhibition of carcinogenic 
activation and induction of detoxification by phase I and phase II xenobiotic metabolizing 
enzymes, respectively, (2) modulation of cell survival and apoptosis, (3) suppression of pro-
inflammatory signaling pathways, and (4) inhibition of angiogenesis, invasion, and 
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metastasis.  This chapter summarizes the diverse molecular targets of resveratrol in the 
prevention and treatment of carcinogenesis. 
 
1.2. Introduction 
 Although advances in chemoprevention and chemotherapy have been achieved, 
cancer remains the second leading cause of death in the United States 
(1)
.  As such, it has 
become increasingly clear that the problem of cancer cannot be solved by traditional 
treatment alone and an alternative approach is needed.  Traditional approaches to cancer 
prevention have included attempts to eliminate carcinogenic agents and to detect and remove 
precancerous lesions; many of these efforts are focused on interrupting, reversing, or 
delaying the neoplastic process and remain largely ineffective and cumbersome 
(2)
.  Yet, 
epidemiological and current laboratory studies suggest consumption of certain fruits and 
vegetables, containing phytochemicals, is associated with reduced cancer risk 
(3)
.  It is 
postulated that these dietary phytochemicals can function as chemopreventive and/or 
adjuvant chemotherapeutic agents 
(3)
.  However, further molecular mechanism-based studies 
are required to evaluate the use of dietary components in cancer chemoprevention and 
chemotherapy. 
 One such phytochemical of particular interest is resveratrol (3, 4’, 5-
trihydroxystilbene), a naturally occurring phytoalexin readily available in the diet and to 
which a plethora of health-promoting effects have been ascribed.  Resveratrol, first identified 
as a bioactive compound in 1992, is found in several plants, particularly in the skin of red 
grapes 
(4)
.  This compound has elicited much attention as a potential anticancer agent since its 
 
 4 
inhibitory effect on carcinogenic processes (initiation, promotion, and progression) was first 
reported in 1997 
(5)
.  Subsequently, numerous studies using both in vitro and in vivo model 
systems have illustrated resveratrol’s capacity to modulate a multitude of signaling pathways 
associated with cellular growth and differentiation, apoptosis, angiogenesis, invasion, and 
metastasis 
(6)
.  Thus, resveratrol modulates multiple signaling pathways that interrupt the 
carcinogenic process and is also capable of extending one or more stages of this process 
(Figure 1.1). 
Despite substantial progress in understanding the molecular basis of resveratrol’s 
anticancer activities, few clinical trials have been undertaken to confirm its use as a 
chemopreventive and/or adjuvant chemotherapeutic agent.  Preclinical studies have 
demonstrated the inhibitory effects of resveratrol in different cancers (Table 1.1) 
(7)
 and its 
ability to act as an adjuvant to traditional chemotherapeutics 
(8-12)
.  As an adjuvant, 
resveratrol potentiates the cytotoxic effects of anticancer drugs given at sub-toxic levels as 
well as alleviate chemotherapeutic drug-associated side effects.   
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Figure 1.1. The chemopreventive and chemotherapeutic effects of resveratrol.  From “Molecular 
targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia Medica © 2011 
Springer Science + Business Media.  All rights reserved. Used with the kind permission of Springer 
Science + Business Media. 
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Table 1.1. Chemopreventive and chemotherapeutic effects of resveratrol: in vivo evidence. 
 
Experimental Model Dose/Route Effects Mechanisms References 
Breast cancer     
SD rats (♀), DMBA- 
     induced  
10 ppm, 127 d; diet  ↑latency period, 
↓incidence/multiplicity 
↓NF-κB activation, 
↓COX2, ↓MMP-9 
(93) 
Colon cancer     
C57B/6 mice, AOM +  
     DSS-induced 
300 ppm, 70 d; diet ↓incidence/multiplicity, 
↓tumor volume  
↓COX2, ↓TNFα, 
↓iNOS 
(80) 
Liver cancer     
SD rats (♀), DENA +  
     phenobarbital-induced 
50-300 mg/kg/d, 20 
wk; diet 
↓incidence/multiplicity ↓proliferation, ↑Bax, 
↓Bcl2 
(63) 
Pancreatic cancer     
Nude mice (♂), MIA     
     PaCa2 cells 
40 mg/kg, 4 wk; p.o. ↓tumor formation, 
↓volume/growth 
↓proliferation, 
↓microvessel density, 
↓NF-κB, ↓cyclin D1, 
↓COX2, ↓MMP9, 
↓survivin 
(12) 
Skin cancer     
B6D2F1 mice (♀),  
     doxorubicin-resistant   
     B16 melanoma cells 
12.5 mg/kg, 30 d; s.c. ↓tumor growth, 
↑survival of tumor 
bearing mice 
 (11) 
SENCAR mice (♀),  
     DMBA-induced 
1-10 µM, 2/wk for 
4wk; topically 
↓epidermal hyperplasia  (25) 
SKH-1 hairless  mice  
     (♀), UVB-induced 
10 µM, 7 treatments 
on alternate days; 
topically 
↓epidermal hyperplasia ↓leukocyte infiltration, 
↓proliferation, 
↓cdk2/6/4, ↓cyclin 
D1/D2,  ↑p53/p21, 
↓MAPK pathway 
(53) 
Swiss albino mice (♀),  
     DMBA-induced 
25-50 µM, 3/wk for 
28 wk; topically 
↓incidence/multiplicity, 
↓tumor volume 
↑apoptosis: ↑p53, 
↑Bax, ↑cytochrome c 
release, ↑caspase 
activation, ↓Bcl2, 
↓survivin, ↓PI3K/Akt 
pathway 
(66) 
From “Molecular targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia 
Medica © 2011 Springer Science + Business Media.  All rights reserved. Used with the kind 
permission of Springer Science + Business Media. 
 
  
 
 7 
A Phase I clinical study is underway to determine potential adverse resveratrol-drug 
interaction(s) with emphasis on CYP3A4 activity; the CYP3A4 enzyme is involved in the 
metabolism of transplant medications/chemotherapies and is inhibited by resveratrol 
(13)
.  
Other clinical trials seek to determine the effects of resveratrol on Wnt signaling in normal 
mucosa and colon cancers (www.clinicaltrials.gov).  Although shown to be well tolerated in 
humans, the bioavailability of resveratrol remains poor 
(14)
.  Thus, in order to recommend use 
of resveratrol as a chemopreventive or adjuvant chemotherapeutic, further studies are 
necessary to enhance bioavailability of this phytochemical as well as to validate identified in 
vitro/in vivo targets of resveratrol.  To this end, studies have begun evaluating techniques to 
enhance resveratrol systemic bioavailability based on combinations with compounds that 
inhibit the in vivo metabolism, nanoparticle-mediated delivery, use of naturally or synthetic 
derivatives, and/or use of conjugated metabolites of resveratrol 
(15)
.  Yet, resveratrol remains 
a promising candidate for the prevention and treatment of cancers.  This chapter summarizes 
identified molecular targets of resveratrol that contribute to its activities in the prevention and 
treatment of carcinogenesis. 
 
 
1.3. Regulation of Phase I and Phase II Xenobiotic Metabolizing Enzymes 
 Oxidative metabolism by phase I enzymes, such as those belonging to the cytochrome 
P450 (CYP) family, results in the conversion of pro-carcinogens to reactive electrophilic 
intermediates, which are further metabolized by phase II enzymes via the conjugation of 
hydrophilic moieties.  Resultant metabolites are detoxified and eliminated.  However, 
inadequate detoxification by phase II enzymes potentiates genotoxicity (e.g. DNA and 
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protein adduct formation) of phase I products, thus initiating the carcinogenic process 
(16, 17)
.  
Reports of modification of both phase I and phase II xenobiotic metabolizing enzymes by 
resveratrol suggest an explanation for the compound’s chemopreventive effect (Figure 1.2).  
Two primary molecular mechanisms have been identified: (1) inhibition of AhR-dependent 
and AhR-independent activation of phase I enzymes and (2) induction of Nrf2-mediated 
activation of phase II enzymes. 
 
 
 
Figure 1.2.  Effect of resveratrol on AhR/Nrf2 signaling pathways.  See text for AhR and Nrf2 
pathway description.  (A) Resveratrol inhibits AhR/ARNT recruitment to XRE-driven promoters (red 
line) and is suggested to displace PAH binding, thus stabilizing cytosolic AhR complex (dotted line); 
see text for refs.  (B) Resveratrol promotes Nrf2 nuclear translocation via Keap1 dissociation.  This 
results in dimerization with small Maf (sMaf) and activation of ARE-driven promoters 
(18)
. 
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1.3.1. Aryl hydrocarbon receptor (AhR) 
 Resveratrol is reported to alter phase I enzyme expression and activity in both an 
AhR-dependent and AhR-independent manner 
(19)
.  The canonical AhR-dependent signaling 
pathway is thought to contribute to carcinogenic initiation by phase I enzyme-activated 
polycyclic/poly-halogenated aromatic hydrocarbons (PAH/PHAH), and inhibition of AhR 
signaling by resveratrol is thought to suppress this initiative process.  Under basal conditions, 
unbound AhR forms a multimeric complex in the cytosol.  However, upon ligand binding 
(e.g. binding by PAH/PHAHs), AhR translocates to the nucleus (shedding the multimeric 
complex), forms a heterodimer with the AhR nuclear translocator (ARNT), and binds to gene 
promoters containing xenobiotic response elements (XREs) resulting in the transactivation of 
phase I enzymes 
(20)
. 
 Several reports demonstrate the inhibitory effects of resveratrol on AhR-mediated 
activation of phase I enzymes.  For example, resveratrol was shown to impair TCDD (2, 3, 7, 
8-tetrachlorodibenzo-p-dioxin)-induced recruitment of AhR and ARNT to the CYP1A1/1B1 
and CYP1A1/1A2 promoter in MCF-7 breast and HepG2 liver cancer cells, respectively, 
resulting in decreased expression 
(21)
.  Resveratrol also effectively blocked TCDD-induced, 
AhR-dependent transcription in both an estrogen receptor (ER)-dependent and ER-
independent manner 
(22, 23)
.  Using ER-positive cancer cells, Perdew et al. 
(22)
 observed that at 
micromolar concentrations, resveratrol reduced the AhR/ARNT complex at the CYP1A1 
promoter, resulting in near-complete inhibition of CYP1A1 expression and metabolic 
activity; however, at nanomolar concentrations, resveratrol repressed AhR-mediated 
induction of CYP1A1 without interfering with AhR association with XREs after TCDD 
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exposure.  On the other hand, MacPherson and Matthews 
(23)
 showed resveratrol’s 
competitive displacement of TCDD from AhR, indicating prevention of TCDD-induced 
CYP1A1/1B1 expression mediated by AhR/ARNT complex recruitment to the promoter in 
both ER-positive and ER-negative breast cancer cells.  Furthermore, resveratrol was 
demonstrated to reverse TCDD-induced, AhR-mediated CYP1A1 and matrix 
metalloproteinase (MMP) 9 expressions in the gastric cancer cell line AGS 
(24)
.   
 Moreover, resveratrol effects phase I enzymes in an AhR-independent manner; the 
phytochemical is shown to directly inhibit the expression and activity of these enzymes.  
Resveratrol effectively blocked CYP1A1 and/or CYP1B1 expression and activity induced by 
B[a]P (benz[a]pyrene), DMBA (7, 12-dimethylbenz[a]pyrene), dioxin, or TCDD in 
differentiating keratinocytes 
(25, 26)
, immortalized bronchial epithelial cells 
(27)
, and breast 
cancer cells 
(19, 28, 29)
.  Resveratrol also suppressed CYP1A1/1B1 expression in vivo utilizing 
a Balb/c animal model 
(30, 31)
.  Furthermore, Mikstacka et al.
(32)
 suggest that the addition of 
thiol- and methoxy-groups to the resveratrol backbone increased selectivity for and inhibition 
of CYP1A1 and CYP1B1.   
 In addition to modulation of CYP1A1/CYP1B1 expression and activity, resveratrol is 
demonstrated to negatively regulate other CYP family members: inhibition of B[a]P-induced 
CYP1A2 and CYP2B expression 
(31)
 and abrogation CYP2E1 catalytic activity 
(33)
 in vivo.  
CYP3A4, which is predominantly overexpressed in colon and liver cancers, has been found 
to be inhibited by resveratrol 
(13)
.  Thus, resveratrol plays a suppressive role in AhR-
dependent and AhR-independent (e.g. effecting CYPs directly) activation of phase I 
enzymes, contributing to the anticancer activity of this dietary phytoalexin.  
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1.3.2. Nuclear factor E2-related factor 2 (Nrf2) 
 Induction of Nrf2 signaling by resveratrol is thought to confer protection against 
phase I enzyme-activated carcinogens and associated carcinogenicity via the transactivation 
of antioxidant and phase II detoxifying enzymes 
(34)
.  Under basal conditions, Kelch-like 
ECH-associated protein 1 (Keap1) sequesters Nrf2 in the cytoplasm, targeting the 
transcription factor for proteasomal degradation.  However, when induced by electrophiles, 
reactive oxygen species, or dietary phytochemicals, Nrf2 dissociates from Keap1 and 
translocates to the nucleus where it dimerizes with small Maf proteins and activates 
antioxidant response element (ARE)-driven promoters 
(18, 34)
.   
 Bishayee et al. 
(35)
 demonstrated that attenuation of DENA (diethyl nitrosamine)-
induced liver carcinogenesis by resveratrol was mediated by increased Nrf2 expression.  
Resveratrol induction of NAD(P)H quinone oxidoreductase (NQO1) expression in TCDD-
treated MCF10F immortalized breast cells involved Nrf2, leading to suppression of DNA 
adduct formation 
(28)
.  NQO1 was also increased by resveratrol after 4-hydroxyestradiol and 
estradiol-3-4-quinone treatment 
(36)
.  Induction of Nrf2 signaling by resveratrol resulted in 
increased expression of NQO1, heme-oxygenase-1 (HO-1), and glutamate cysteine ligase 
(GCL) catalytic subunit in cigarette smoke extract (CSE)-treated bronchial epithelial cells 
(37)
.  Kode et al. 
(38)
 observed restored glutathione levels in CSE-treated A549 lung alveolar 
epithelial cancer cells by resveratrol; this effect was mediated via Nrf2-induced GCL 
expression and activity through the inhibition of CSE-modified Nrf2 posttranslation.  
Resveratrol protected primary hepatocytes exposed to oxidative stress via increased Nrf2-
mediated NQO1, catalase, superoxide dismutase, glutathione reductase, glutathione 
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peroxidase, and glutathione-S-transferase expression 
(39)
.  Furthermore, resveratrol increased 
NQO1 expression and activity in K562 leukemia cell line, which was associated with 
resveratrol-induced Nrf2/Keap1 complex disruption, Nrf2 nuclear translocation, and 
subsequent binding to ARE within the NQO1 promoter 
(40)
.  These results indicate that Nrf2 
is a key protein that controls resveratrol-induced anti-tumorigenesis in several cancers.  In 
contrast, Kawai et al. 
(41)
 observed Nrf2 cytoplasmic accumulation and inhibition of Nrf2-
dependent transcription by resveratrol, presumably mediated through induced sirtuin 1 
(SIRT1) deacetylase activity, in both K562 leukemic and HepG2 hepatocellular carcinoma 
cell lines.  Thus, resveratrol could affect not only translocation but also accumulation of 
Nrf2, potentially contributing to these context-dependent observations.   
 
1.4. Modulation of Cell Cycle Progression and Apoptosis 
 The deregulation of cell cycle machinery and evasion of apoptosis, which contribute 
to aberrant cell proliferation and survival, are considered a fundamental hallmark of cancer 
development 
(42, 43)
.  Therefore, identification of agents that target this abnormal signaling 
offers an important strategy for both chemoprevention and chemotherapy.  Resveratrol is one 
such compound; several studies have demonstrated that the anti-proliferative effect of 
resveratrol on cancer cells is attributable to inhibition of multiple pro-survival signaling 
pathways 
(44, 45)
.   
 
 
 
 
 13 
1.4.1. Cell cycle proteins 
 Eukaryotic cell replication involves a series of processes collectively known as the 
cell cycle 
(46)
.  The cell cycle is divided into two major events: (1) interphase (divided into 
four phases: G0, G1, S, and G2), in which the cell grows and accumulates nutrients, and (2) 
mitosis (M), where the cells divide into two daughter cells.  Proper functioning of the cell 
cycle is important; the presence of numerous internal checkpoints allows the cell to detect 
genetic damage and stalls cell cycle progression until these aberrations are repaired or 
apoptosis is triggered.  Failure of DNA quality control by checkpoints (and loss of regulatory 
balance) facilitates uncontrolled cell proliferation and the development of cancer 
(46)
.   
 Cyclins and cyclin-dependent kinases (CDKs) are key regulatory molecules 
governing the ordered processes of the cell cycle.  Activation of CDKs by cyclins results in 
the phosphorylation of target proteins, leading to the activation or inactivation of these 
targets, and facilitates progression into the next phase of the cell cycle.  Of the many cyclins, 
cyclin D1 is an important cell cycle regulator involved in the G1/S phase transition and in the 
regulation of proliferation and differentiation.  Cyclin D1, produced in response to growth 
factors, is often increased in various cancers due to deregulated degradation 
(43)
.   
 Resveratrol is reported to induce G1/S or G2/M phase cell cycle arrest in many cancer 
cell lines, attributable to the modulation of cyclin-associated CDK proteins 
(44)
.  Experiments 
in cell culture revealed that down-regulation of cyclin D1 and/or CDK4/6 by resveratrol 
resulted in the inhibition of cell proliferation, growth arrest, and subsequent induction of 
apoptosis.  Such an effect was observed in studies of the bladder 
(47)
, breast 
(48)
, colon 
(49)
, 
liver 
(50)
, multiple myeloma 
(8)
, pancreas 
(12)
, prostate 
(51, 52)
, and skin cancer cells 
(11, 53)
.  
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These results were also observed in vivo utilizing an UVB-induced model of skin 
tumorigenesis 
(54)
.  Resveratrol treatment of colorectal cancer cells also inhibited expression 
of cyclin D1 and its complex formation with CDK4 
(55)
; it is likely that resveratrol-induced 
cyclin D1 suppression may result from -catenin inactivation in colorectal cancer cells and 
should be considered a molecular target in these cancers 
(49)
.  Moreover, treatment with 
resveratrol potentiated the cytotoxic effects of the chemotherapeutic drugs doxorubicin and 
gemcitabine in chemo-resistant B16 melanoma and pancreatic cancer cells, respectively, in 
vitro and inhibited tumor growth in vivo 
(11, 12)
.   
 The CDK inhibitor p21 interacts with cyclin-CDK complexes to negatively regulate 
their expression and is responsible for the G1 phase arrest phenotype 
(43)
.  In contrast to 
cyclin D1, resveratrol-mediated cell cycle arrest is associated with p53-mediated p21 
expression.  Activation of p21 or p27 by resveratrol was observed in bladder 
(47)
, breast 
(48)
, 
liver 
(56)
, lung 
(57)
, prostate 
(51)
, and skin cancer cells 
(53, 54)
.  Cell cycle arrest was associated 
with apoptosis.  Interestingly, Castello and Tessitore 
(58)
 demonstrated resveratrol inhibition 
of U937 leukemic monocyte lymphoma cell proliferation was associated with increased 
cyclin A and cyclin E expression, concomitant p21 and ribonucleotide reductase inhibition, 
and the absence of apoptosis.   
 
1.4.2. Apoptosis 
 Apoptosis, or programmed cell death, involves a series of biochemical events that 
lead to a variety of morphological changes such as blebbing, cell membrane asymmetry and 
attachment, cell shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal 
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DNA fragmentation 
(59)
.  Apoptosis removes damaged and unwanted cells and maintains 
tissue integrity and function 
(59)
. 
 p53 tumor suppressor:  The tumor suppressor protein p53 is a critical transcription 
factor involved in the regulation of cell proliferation and apoptosis; as such, it is a key 
mediator in the prevention of carcinogenesis 
(60)
.  It has been shown that resveratrol can cause 
apoptosis through p53-dependent and p53-independent pathways 
(44)
.  Several groups, 
including our laboratory, have implicated the activation of p53-dependent pathway(s) in the 
observed anti-proliferative effects of resveratrol.  For example, Heiss et al. 
(61)
 demonstrated 
that chronic administration of resveratrol at a sub-apoptotic dose resulted in senescent-like 
growth arrest in different carcinoma cell lines.  This effect was due to increased reactive 
oxygen species generation, ataxia telangiectasia mutated kinase (ATM) and p53 activation 
(via p38MAPK-mediated p53 phosphorylation at serine 15), induction of p21, and 
subsequent induction of senescence.  Utilizing both in vitro and in vivo models of 
tumorigenesis and carcinogenesis, resveratrol is also shown to induce apoptosis via activation 
of both intrinsic (mitochondria-mediated) and extrinsic (death receptor-mediated) pathways 
(44)
.  Resveratrol altered the Bax:Bcl2 protein ratio in the A431 epidermoid cancer cell line, 
leading to mitochondrial membrane depolarization and subsequent induction of caspase-
dependent apoptosis, presumably mediated through p53 activation 
(62)
.  Similar results were 
observed in breast 
(63)
 and in the DENA-initiated, phenobarbital-promoted in vivo model of 
liver carcinogenesis 
(64)
.  Resveratrol increased p53-mediated expression of pro-apoptotic 
proteins (e.g. Bax, Bak, Bim, PUMA, Noxa, etc.) and the release of mitochondrial proteins 
(e.g. cytochrome c, Smac/DIABLO, etc.) to the cytosol, thus triggering suppression of 
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inhibitors of apoptosis proteins (Bcl2, Bcl-XL, survivin, XIAP, etc.) and caspase activation 
in various cancer cell lines 
(9, 10, 65-67)
.  In addition, resveratrol induced the redistribution of 
death receptors to membrane lipid rafts in colorectal and multiple myeloma/T cell leukemia 
cancer cells, thus sensitizing these cells to death receptor-mediated apoptosis 
(68, 69)
.  
Furthermore, resveratrol sensitized TNF-related apoptosis-inducing ligand (TRAIL)-
dependent cell death in androgen-sensitive and androgen-insensitive prostate cancer cells 
(9, 
10)
.   
  How resveratrol increases p53 expression is not clear; it is believed that resveratrol 
treatment causes DNA damage, which facilitates p53 activation.  Tyagi et al. 
(70)
 observed 
resveratrol-induced cell cycle arrest was mediated through increased Cdc2 tyrosine 15 
phosphorylation via the activation of the DNA damage pathway (i.e. ATM/ATR-Chk1/2-
Cdc25 pathway).  Resveratrol treatment also suppressed the metastasis-associated protein-
1/nucleosome remodeling deacetylation complex, allowing for increased p53 acetylation and 
subsequent activation of pro-apoptotic genes 
(71)
.   
 Forkhead box, subgroup O (FoxO) transcription factor: Proteins known as FoxO, 
divergent members of the Fox/winged-helix transcription factor superfamily, are recognized 
tumor suppressors that play a critical role in cell fate decisions 
(72)
.  Composed of four 
members (FoxO1, 3, 4, and 6), FoxO transcription factors coordinate the expression of genes 
involved in diverse cellular processes, including cell cycle progression, apoptosis, and 
oxidative stress response.  The function of FoxO proteins is regulated by posttranslational 
modification(s), specifically phosphorylation and acetylation, which dictates their subcellular 
localization and transcriptional activity 
(73)
. 
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 Abrogation of FoxO function occurs in numerous cancers due in large part to the 
constitutive activation of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, a key 
regulator of FoxO activity.  PI3K/Akt-mediated phosphorylation results in the inactivation of 
FoxO transcription factors.  FoxO phosphorylation by PI3K/Akt facilitates their interactions 
with 14-3-3 chaperone proteins and nuclear export; cytoplasmic sequestration inhibits FoxO-
dependent transcription 
(72)
.  FoxOs are also regulated by de/acetylation in response to 
oxidative stress.  Several studies identify FoxOs as targets of the NAD-dependent class III 
histone/protein deacetylase SIRT1.  Under conditions of oxidative stress, SIRT1 forms a 
complex with and deacetylates FoxO transcription factors, resulting in the preferential 
activation of cell cycle arrest/stress resistance-related genes, thereby promoting cell survival 
(74-76)
.  Furthermore, silencing of SIRT1 resulted in FoxO4-mediated apoptosis in epithelial-
derived cancer cells 
(77)
.  Thus, targeting these inhibitory pathways may prove advantageous 
in the prevention/treatment of cancers. 
 The activation of FoxO transcription factors is implicated in the observed anticancer 
activities of resveratrol.  Using prostate cancer cells, Chen et al. 
(78)
 demonstrated 
resveratrol’s ability to inhibit the phosphorylation of PI3K/Akt (i.e. PI3K/Akt inactivation) 
resulted in decreased FoxO phosphorylation.  Resveratrol increased nuclear translocation, 
DNA binding affinity, and transcriptional activity of FoxOs.  Furthermore, the anti-
proliferative/pro-apoptotic effect (Bim/TRAIL/DR4/DR5/p27
Kip
 induction and cyclin D1 
inhibition) of resveratrol on prostate cancer cells is FoxO-dependent.  Similar results were 
also observed in vivo 
(79)
. A schematic representation of resveratrol-mediated FoxO 
regulation is shown in Figure 1.3.   
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 As described, SIRT1 induced FoxO deacetylation results in the preferential activation 
of cell survival-related genes.  Being that resveratrol is considered a SIRT1 agonist, although 
currently controversial, one could speculate that the activation of a FoxO-mediated pro-
survival mechanism may be induced by resveratrol-increased SIRT1 deacetylase activity.  
Indeed, this is demonstrated in cardiomyocytes; resveratrol, presumably through SIRT1, 
increased FoxO transcriptional activation of stress resistance-related genes and subsequent 
phosphorylation by Akt 
(80)
.  However, currently, the resveratrol/SIRT1/FoxO signaling axis 
has not been studied in cancer cells thus allowing one to infer such an effect is context 
dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Effects of resveratrol on the FoxO signaling pathway.  See text for FoxO pathway 
description.  Resveratrol is demonstrated to inhibit Akt activation and subsequent FoxO 
phosphorylation and nuclear export.  In contrast, resveratrol-induced FoxO expression facilitates 
transactivation of forkhead response element (FHRE)-driven promoters (see text for refs.)GF, growth 
factor; RTK; receptor tyrosine kinase.  
 
 19 
 
 
 
1.5. Suppression of the Inflammatory Signaling Pathway 
 Chronic inflammation contributes to the development of many diseases, including 
cancer 
(81)
.  For example, chronic colitis is associated with an increased risk of developing 
colorectal cancer, and the susceptibility to cancer increases when the tissue is chronically 
inflamed 
(82)
.  Many tumors contain non-cancer cells, including immune and vascular cells 
that are important in inflammation.  The critical molecular interactions between neoplastic 
cells and inflammatory cells remain unknown, but both pro- and anti-inflammatory mediators 
are likely involved 
(81)
.  Thus, it is clear the link between inflammation and cancer is strong 
and that the interplay between the immune system and the development and remission of 
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cancer is critical.  These inflammatory processes contribute to the development and 
progression of carcinogenesis, including tumor growth, angiogenesis, invasion, and 
metastasis 
(81)
.   
 
1.5.1. Nuclear factor- B (NF- B) 
 A key mediator of inflammation-induced cellular transformation is the transcription 
factor NF- B.  Cytoplasmic sequestration by I B  prevents NF- B-dependent 
transactivation.  Upon activation, IKK  phosphorylates I B  resulting in its degradation, and 
facilitates NF- B nuclear translocation and subsequent activation of transcription 
(83)
. 
 It has been postulated that the anticancer effects of resveratrol are attributable to the 
inactivation of NF- B-dependent signaling.  Resveratrol inhibited IKK -mediated I B  
phosphorylation, resulting in increased I B  expression, NF- B cytoplasmic retention, and 
subsequent NF- B inactivation 
(84, 85)
.  Resveratrol also blocked interleukin-1  (IL-1 )-, 
tumor necrosis factor  (TNF )-, and HO-1-induced NF- B activation 
(86-88)
.  Resveratrol 
treatment of multiple myeloma cells resulted in cell cycle arrest and suppression of NF- B-
dependent signaling related to proliferation (cyclin D1), survival (Bcl-2, Bcl-XL, XIAP, c-
IAP, and survivin), angiogenesis (vascular endothelial growth factor, VEGF), and metastasis 
(MMP9 and IL-6) 
(8, 89)
.  Similar results were observed in vivo using a DENA-initiated liver 
carcinogenesis model 
(90)
 and Mia PaCa-2 orthotopic model of pancreatic cancer 
(12)
.  
Furthermore, resveratrol prevented PMA (phorbol 12-myristate 12-acetate)-induced HT1080 
fibrosarcoma cell adhesion to endothelial cells via modulation of intercellular adhesion 
molecule-1 expression and NF- B activity 
(91)
.  Taken together, it is clear that resveratrol not 
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only curbs expression of NF- B, but also impedes the phosphorylation of I B  thereby 
keeping the constitutive NF- B subunit in an inactive state, resulting in suppression of the 
inflammatory and pro-tumorigenic changes associated with this pathway (Figure 1.4). 
 
1.5.2. Cyclooxygenase-2 (COX-2) 
 Overexpression of COX-2 is suggested to contribute to tumor development via 
modulation of the multiple stages of tumorigenesis: cell survival signaling pathways, 
angiogenesis, invasion, and metastasis 
(92)
.  Resveratrol inhibited the expression and activity 
of COX-2 through direct interaction with the enzyme’s catalytic domain 
(93)
.  Zykova et al. 
(94)
 demonstrated inhibition of COX-2 activity (prostaglandin E2 synthesis), inhibition of 
colony formation, and suppression of anchorage-independent growth in HT29 colon cancer 
cells by this compound; COX-2 inhibition was absolutely required for resveratrol-mediated 
activity.  Resveratrol also reduced COX-2 expression in DENA-initiated liver 
(90)
, DMBA-
initiated mammary 
(95)
, and TPA (12-o-tetradeconoylphorbol-13-acetate)-initiated skin 
(96)
 
carcinogenesis.  Furthermore, using a DSS (dextran sodium sulfate)-induced mouse model of 
colitis, resveratrol treatment was shown to reduce COX-2 expression 
(97, 98)
; similar results 
were observed in DSS-induced, azoxymethane-promoted model of colitis-driven colon 
cancer 
(82)
. 
 
1.5.3. Pro-inflammatory cytokines: Tumor necrosis factor  (TNF ) and interleukins (ILs) 
 Pro-inflammatory cytokines, such as TNF  and ILs, are important mediators of both 
inflammation-related cancer and cancer-related inflammation.  Expression of these cytokines 
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is associated with carcinogenesis mediated via the activation of the NF- B signaling pathway 
(81, 99)
.  Resveratrol reversed colitis-associated expression of TNF , IL-6, and IL-1  induced 
by DSS 
(82, 97, 98)
.  Resveratrol suppressed IL-1 -stimulated cell proliferation, reduced IL-1 -
production, and IL-1 -induced NF- B activation in acute myeloid leukemia cells 
(86)
.  Using 
streptozotocin-nicotinamide-induced diabetic rats, Palsamy and Subramanian 
(100)
 reported 
that resveratrol ameliorates induction of pro-inflammatory cytokines (e.g. TNF , IL-1 , IL-
6) in pancreatic -cells.  Leiro et al. 
(101)
 proposed the anti-inflammatory activity ascribed to 
resveratrol is related, in part, to the inhibition of TNF  and IL-1  mRNA processing, which 
resulted in reduced migration of head and kidney leukocytes in response to inflammatory 
stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Effects of resveratrol on the NF- B signaling pathway.   See text for NF- B pathway 
description.  Resveratrol is demonstrated it inhibit NF- B signaling at all steps (see text for refs).   
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1.6. Inhibition of Angiogenesis, Invasion, and Metastasis  
 Angiogenesis, the formation of new blood vessels, is critical to tumor development 
and growth, invasion, and metastasis 
(102)
.  Neovascularization facilitates cell dissociation 
from the primary tumor site, entry into circulation, and establishment of the tumor(s) at a 
secondary site (a process termed metastasis) 
(103-105)
.  Disruption of the angiogenic and 
metastatic signaling cascades is another mechanism by which resveratrol exerts its 
chemotherapeutic effect. 
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1.6.1. Hypoxia inducible factor-1  (HIF-1 ) and vascular endothelial growth factor (VEGF) 
 Adaptation to hypoxia by tumor cells is mediated by HIF-1 , which regulates the 
expression of proteins, such as VEGF, associated with angiogenic and invasive signaling 
cascades 
(106)
.  Treatment with resveratrol reduced expression of HIF-1  and VEGF in 
ovarian cancer cells; resveratrol-mediated activity was attributed to inactivation of PI3K/Akt 
and protein translational regulators, enhancement of HIF-1  proteasomal degradation, and 
subsequent suppression of VEGF 
(107)
.  These results were also observed in tongue squamous 
cell carcinoma 
(108)
 and lysophosphatidic acid-stimulated ovarian cancer cells 
(109)
.  VEGF 
expression was also reduced in multiple myeloma 
(89)
 and endometrial cancer cells 
(110)
.  
Additionally, the anti-migratory/angiogenic effects of resveratrol observed in human 
umbilical vein epithelial cells was FoxO-dependent and predicated on PI3K/Akt pathway 
inhibition; this observation was associated with decreased VEGF expression 
(111)
.   
 
1.6.2. Matrix metalloproteinase 2 and 9 (MMP2 and MMP9) 
 Cell invasion and metastasis are facilitated via the proteolytic degradation of 
basement membrane and connective tissue; this degradation of extracellular matrices creates 
a channel by which tumors escape into circulation.  MMPs are essential factors in this 
process 
(81, 103)
.  Numerous reports illustrate the anti-invasive and anti-metastatic properties of 
resveratrol.  Treatment with resveratrol inhibited heregulin- 1-mediated MMP9 expression 
in breast cancer cells through the inactivation of ERK1/2 signaling resulting in suppression 
of invasion 
(112)
.  TNF -mediated MMP9 expression and invasion was also reduced in 
resveratrol-treated hepatocellular carcinoma cells; this suppression was associated with 
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down-regulation of NF- B signaling 
(87)
.  Inactivation of NF- B signaling in lung 
adenocarcinoma cells also contributed to the anti-invasive effect of resveratrol and led to 
inhibition of HO-1-induced MMP9 expression, migration, and invasion 
(88)
.  Resveratrol 
blocked insulin growth factor-1 (IGF-1)-mediated cell migration in vitro through inactivation 
of the PI3K/Akt signaling pathway and down-regulation of MMP2 induced by IGF-1 
(113)
.  
Moreover, resveratrol blunted TNF -induced monocyte adhesion and migration through 
modulation of adhesion molecules and MMP2 enzymatic activity 
(114)
. 
 
1.7. Other Molecular Targets 
1.7.1. Topoisomerase II 
 Topoisomerases are ubiquitously expressed enzymes that regulate the topological 
state of DNA; these enzymes remove knots and tangles from the genome through the 
winding and unwinding of DNA, generating transient double-stranded breaks in the DNA 
double helix to control cell division and proliferation.  In malignant tumor cells, this enzyme 
is overexpressed when compared to normal, quiescent cells; thus, topoisomerase II has been 
suggested as a potential chemopreventive target 
(115)
.  Resveratrol is demonstrated to inhibit 
topoisomerase activity.  Treatment of glioblastoma cells with the compound interfered with 
decatenation (i.e. unwinding of DNA) by topoisomerase; these authors suggest resveratrol 
acted as a “topoisomerase poison” due to the prolongation of the topoisomerase-DNA 
complex 
(116)
. 
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1.7.2. Human telomerase reverse transcriptase (hTERT) 
 Addition of hexametric repetitive sequences (referred to as telomeres) to 
chromosomal ends by telomerase ensures and maintains genomic stability.  With each cell 
division, telomeres progressively shorten until a critical length is reached and the cell 
undergoes senescence or apoptosis.  In most cancers, telomerase is highly activated resulting 
in tumor cell immortalization due to the maintenance of telomeres.  This immortalization is 
associated with increased expression of the telomerase catalytic subunit, hTERT 
(117)
.  
Therefore, targeting telomerase and its catalytic subunit hTERT provides an additional 
mechanism by which anticancer agents exert chemopreventive/chemotherapeutic effects.  
Resveratrol has been shown to suppress telomerase activity in breast 
(118)
 and colon 
(119)
 
cancer cells associated with decreased nuclear levels of hTERT.  Furthermore, resveratrol 
treatment of osteosarcoma and lung cancer cells induced telomeric instability, 
phosphorylation of histone H2AX and p53, and activation of DNA damage signaling 
(120)
. 
 
1.8. Identification of Novel Molecular Targets 
 To identify novel molecular targets that mediate the anti-cancer activities of 
resveratrol, our laboratory performed microarray analysis using HCT-116 human colorectal 
cancer cells treated with resveratrol (50 µM) for 24 h (Table 1.2).  Among the 519 genes 
altered by resveratrol, three genes, ATF3, NAG-1, and DDIT3 were of particular interest due 
to their suggested involvement as negative regulators of tumorigenesis and carcinogenesis.   
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Table 1.2. Alteration of gene expression profiles of HCT-116 colorectal cancer cells by 
resveratrol (50 μM).   Select up- and down-regulated genes from microarray analysis. 
 
Gene Symbol Gene Name GenBank No. Up/Down 
DDIT3 DNA-damage-inducible transcript 3 NM_004083 Up 
ATF3 Activating transcription factor 3 NM_004024 Up 
COBRA1 Cofactor of BRCA1 NM_015456 Up 
OR8B8 Olfactory receptor, family 8, subfamily B, member 8 NM_012378 Up 
AADACL1 Arylacetamide deacetylase-like 1 NM_020792 Up 
PLK3 Polo-like kinase 3 (Drosophila) NM_004073 Up 
PCK2 Phophoenolpyruvate carboxykinase 2 (mitochondrial) NM_004563 Up 
NAG-1 NSAID-activated gene-1 NM_004864 Up 
WNT16 Wingless-type MMTV integration site family, member 16 NM_016087 Down 
C4orf18 Chromosome 4 open reading frame 18 NM_016613 Down 
FANCC Fanconi anemia, complementation group C NM_000136 Down 
PDE4B Phosphodiesterase 4B NM_001037 Down 
IGFBP7 Insulin-like growth factor binding protein 7 NM_001553 Down 
From “Molecular targets of resveratrol in carcinogenesis” in Evidence-based Anticancer Materia 
Medica © 2011 Springer Science + Business Media.  All rights reserved. Used with the kind 
permission of Springer Science + Business Media. 
 
1.8.1. Activating transcription factor 3 (ATF3) 
ATF3 is a member of the ATF/cAMP response element binding protein (CREB) 
family of bZIP transcription factors and is characterized as a stress inducible/adaptive 
response gene 
(121)
.  Much controversy exists as to the role of ATF3 in tumorigenesis due in 
part to the observation of both positive and negative effects.  Recently, a dichotomous role 
was reported for ATF3 in cancer development; the authors concluded its role as a tumor 
suppressor or oncogene is dependent on cell context and the extent of malignancy 
(122)
.  
However, several lines of evidence suggest that ATF3 may function as a tumor suppressor, 
which will be discussed further in Chapter 3 in addition to our recent findings.   
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1.8.2. Nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) 
NAG-1, a divergent member of the transforming growth factor β superfamily of 
cytokines, is suggested to play a role in a number of cellular processes, including 
inflammation and cell survival.  NAG-1 was first identified by Baek et al. 
(123)
 through PCR-
based subtractive hybridization from an NSAID-induced library in human colorectal cancer 
cells.  NAG-1 was shown to be highly expressed in mature intestinal epithelial cells and 
significantly reduced in human colorectal carcinomas and neoplastic intestinal polyps of Min 
mice 
(124)
.  NAG-1 overexpression reduced cell viability of breast cancer cells by up to 80% 
(125)
 and treatment of prostate cancer cells with purified NAG-1 induced apoptosis 
(126)
.  In 
addition, NAG-1 transgenic mice are resistant to the development of intestinal tumors 
following treatment with azoxymethane or by introduction of a mutant APC gene 
(127)
.  
Furthermore, subsequent studies have identified NAG-1 induction by a number of dietary 
and naturally occurring compounds demonstrated to possess anticancer activity.  These 
include genistein 
(128)
, epicatechin gallate 
(129)
, indole-3-carbinol 
(130)
, conjugated linoleic acid 
(131)
, berberine 
(132, 133)
, 6-gingerol 
(134)
, platycodon D 
(135)
,  capsaicin 
(136)
, Astragalus 
saponins 
(137)
, and the isoflavonoid formononetin 
(138)
.  Increased NAG-1expression 
contributed to the inhibition of cell proliferation and induction of apoptosis by these 
compounds.  Additionally, we and others have shown NAG-1 up-regulation by resveratrol 
resulted in increased p53-mediated cell death in colorectal, lung, and osteosarcoma cancer 
cells 
(139)
 and inhibition of cell proliferation in pancreatic cancer cells 
(140)
.   
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1.8.3. DNA-damage-inducible transcript 3 (DDIT3) 
 DDIT3 is a critical mediator in the induction of cell cycle arrest and/or apoptosis in 
response to ER stress.  Transcriptional activation by ER stress results in downstream 
regulation of genes involved in the modulation of cell survival.  For example, DDIT3 
expression inhibits Bcl2 and leads to Bax translocation to the mitochondria resulting in 
activation of the intrinsic pathway of apoptosis 
(141)
.  In several studies, resveratrol is 
demonstrated to increase DDIT3 expression in colon 
(142, 143)
 and leukemia 
(144)
 cancer cells.  
Increased DDIT3 expression contributed to induction of cell cycle arrest and/or induction of 
apoptosis by resveratrol. 
 
1.8.4. Other potential targets 
 Although gene alteration by resveratrol has yet to be validated, each of the 
aforementioned genes (refer to Table 1.2) is suggested to act as either a negative or positive 
regulator of tumorigenesis.  COBRA1, an integral component of negative elongation factor 
complex, is demonstrated to inhibit estrogen-dependent transcription and growth of breast 
cancer cells in vitro.  Furthermore, loss of COBRA1 is associated with breast cancer 
progression and metastasis 
(145)
.  Plk3, whose expression is rapidly increased in response to 
DNA damage and cellular stress, is believed to behave as a tumor suppressor gene and serve 
as a “functional link” in p53-induced cell cycle arrest and apoptosis 
(146)
.  Thus, induction of 
COBRA1 or Plk3 may play a role in resveratrol-mediated inhibition of proliferation or 
induction of apoptosis in colorectal and other cancers.  On the other hand, down-regulation of 
WNT16, FANCC, or PDE4B by resveratrol may lead to enhanced inhibition of cell growth 
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or sensitization to chemotherapy.  For example, overexpression of WNT16 is associated with 
oncogene-induced senescence via regulation of p53 activity 
(147)
 and enhanced cell 
proliferation and clonogenicity of basal cell carcinomas 
(148)
.  Disruption of FANCC, which 
results in deactivation of the Fanconi anemia pathway, sensitizes cancer cells to DNA 
damage and growth inhibition induced by DNA interstrand-cross-linking agents thereby 
abrogating chemo-resistance 
(149-151)
.  Moreover, increased PDE4B expression is associated 
with inactivation of cAMP and abrogation of growth inhibitory effects of cAMP 
(152, 153)
. 
 
1.9. Summary 
 As discussed in previous sections, resveratrol is demonstrated to modulate the 
expression and/or activity of proteins involved in critical pathways of carcinogenesis.  These 
include carcinogen activation and detoxification, inflammation, angiogenesis, invasion and 
metastasis.  Although numerous molecular targets have been identified, the underlying 
mechanisms involved in the antitumor/anticancer activities of resveratrol are not completely 
understood.  Thus, the objective of the studies discussed herein sought to investigate the 
effect of resveratrol treatment on gene modulation in human colorectal cancer cells in order 
to identify and characterize a novel molecular target(s) that may mediate the anticancer 
activities of resveratrol.    
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Materials and Experimental Methods 
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2.1. Cell Lines and Reagents 
 All human cancer cell lines were purchased from American Type Culture Collection 
(Manassas, VA) unless otherwise stated; authentication occurred via short tandem repeat 
profiling, monitoring of cell morphology, and karyotyping.  SqCC/Y1 head and neck 
squamous cell carcinoma cell line was generously provided by Dr. Dong M. Shin (Emory 
University, Atlanta, GA) and characterized previously 
(154)
.  HCT-116 and HT-29 colorectal 
carcinoma cells were maintained in McCoy’s 5A culture medium; SW480 colorectal 
carcinoma cells were maintained in RPMI-1640 culture medium.  Caco-2 colorectal 
carcinoma cells and SqCC/Y1 were grown in DMEM culture medium.  A549 lung epithelial 
carcinoma cells, LoVo colorectal carcinoma cells, and PC3 prostate adenocarcinoma cells 
were cultured in Ham’s F12 medium.  All media were supplemented with 10% fetal bovine 
serum, penicillin (100 U/mL), and streptomycin (100 μg/mL).  Resveratrol was purchased 
from Alexis Biochemicals (San Diego, CA), 3’3-diindolymethane (DIM) from Sigma 
Aldrich (St. Louis, MO), and trichostatin A (TSA) and cycloheximide (CHX) from Fisher 
Scientific (Pittsburgh, PA).  All chemicals were dissolved in either dimethylsulfoxide 
(DMSO) or ethanol.  ATF3 (sc-188), Egr-1 (sc-110), KLF4 (GKLF4; sc-20691), and -actin 
(sc-47778 HRP) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA).  Acetylated Lysine (#9441), phosphor-SIRT1 (Ser27; #2327), and phosphor-SIRT1 
(Ser47; #2314) antibodies were purchased from Cell Signaling Technology (Danvers, MA).  
Anti-SIRT1 (clone 10E4; #04-1557) antibody was purchased from Millipore (Billerica, MA).   
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2.2. Construction of Plasmids 
 For deletion analysis of the ATF3 promoter, pATF3 -1850/+34 
(155)
 was serially 
deleted using the Erase-a-Base System (Promega, Madison, WI) according to manufacturer’s 
protocol.  The pATF3 -514 del Egr-1 reporter construct was previously described 
(156)
.  
Putative binding sites of KLF4 within the -514 bp region of the ATF3 promoter were deleted 
using Stratagene’s QuikChange II Site Directed Mutagenesis Kit (La Jolla, CA) with KLF4-
A and KLF4-B deletion primers (see Table 2.1).  pATF3 -514 del Egr-1 KLF4 reporter 
construct was generated using pATF3 -514 del Egr-1 and KLF4-A deletion primers as 
described.  Deletions were confirmed by DNA sequencing.  The ATF3 (pCG-ATF3) and 
SIRT1 (pBABE/T1) expression vectors were kindly provided by Drs. Tsonwin Hai (Ohio 
State University, Columbus, OH) and Thomas E. Eling (NIEHS, Research Triangle Park, 
NC), respectively.  KLF4 (pcDNA3.1/His/V5/KLF4) expression vector was generated using 
human KLF4 specific primers (see Table 2.1).  Egr-1 wild type (pcDNA3.1/NEO/Egr-1; 
WT) expression vector was described previously (157); Egr-1 del AD, del ZD2, and 
KDKK aDaa mutation constructs were generated using specific primers (see Table 2.1).  
Sp1 (pCMV-Sp1) and p53 (pcDNA3.1/myc/His/p53) expression vectors were previously 
described 
(139, 158)
.  The pNAG-133/+41 and pEBS1
4
luc reporter constructs were described by 
Baek et al. 
(157, 158)
.   
 
2.3. Microarray Analysis 
 HCT-116 colorectal cancer cells were treated with DMSO or resveratrol (50 or 100 
μM) for 24 h.  Total RNA was amplified using Agilent Low RNA Input Fluorescent Linear 
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Amplification Kit (Santa Clara, CA) protocol.  Starting with 500 ng of total RNA, Cy3- or 
Cy5-labeled cRNAs was produced according to the manufacturer’s protocol.  For each two-
color comparison, 750 ng of each Cy3- and Cy5-labeled cRNAs was mixed and fragmented 
using Agilent in situ Hybridization Kit protocol.  Hybridizations were performed for 16 h in a 
rotating hybridization oven using Agilent 60-mer oligo microarray processing protocol.  Data 
was obtained using Agilent Feature Extraction Software (v7.5) using defaults for all 
parameters.  Intensity plots were rated for each ratio experiment, and genes were considered 
“signature genes” if the p value was less than 0.001.  Functional annotation of genes was 
performed according to the Gene Ontology Consortium 
(http://www.geneontology.org/index/shtml) by Gene Spring (v7.3). 
 
2.4. Reverse Transcription and Quantitative Reverse Transcription Polymerase Chain 
Reaction (RT-PCR and qRT-PCR) 
 Total RNA was isolated from HCT-116 cells treated with DMSO or resveratrol (50 
μM) using 5 Prime Perfect RNA Cell/Tissue Kit (Gaithersburg, MD) and 1 μg of RNA was 
reverse transcribed using Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Rockford, 
IL).  One μL of synthesized DNA was added to 24 μL of PCR reaction mixture containing 
human specific gene primers (see Table 2.2).  Thermo cycling occurred as follows: initial 
denaturation at 94 C for 3 min followed by 30 (ATF3, DKK1, Egr-1, HO-1, KLF4, NAG-1, 
Nur77 and PDE4B) and 25 (GAPDH) cycles at 94 C for 1 min, 55 C for 1 min, 72 C for 1 
min, and final extension at 72 C for 10 min.  PCR products were electrophoresed on 1.4% 
agarose gel and photographed under ultraviolet light.  The intensity of each band was 
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quantified using Scion Image software (Scion Corp., Frederick, MD) and normalized to 
GAPDH, an internal control.  Quantitative reverse transcription PCR (qRT-PCR) was 
performed according to Fast SYBR Green Master Mix protocol (Applied Biosystems, 
Carlsbad, CA) and analyzed using MyIQ Single Color Real-time PCR Detection System 
(Bio-Rad Laboratories, Hercules, CA).  
 
 
 
Table 2.1. Primers used for the construction of plasmids. 
 
Construct Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
del KLF4-A ccccctctctttcggccccgccttggcccc cggggccgaaagagagggggcactggtgatg 
del KLF4-B ggcccctcctccttcctccgctcggttcgg cggaggaaggaggaggggccaaggcggggc 
pM/Egr-1 ttgaattcgccgcggccaaggccgag ttaagcttgcaaatttcaattgtcc 
del AD catcacctatggcctagtgagcatgaccaaccc
ac 
tcactaggccataggtgatggggggcagtcgagt
g 
del ZD2 gccctcccagttcgcctgcgacatctgtggaag
aa 
cgcaggcgaactggaagggcttctggcctgtgtg
g 
KDKK aDaa 
(Egr-1 aDaa) 
cggcaggcggacgcggcagcagacaaaagt
gttgtggcctcttcg 
gtctgctgccgcgtccgcctgccgcaagtggatct
tggtatgcc 
KLF4 and 
pVP16/KLF4 
cgaattctatggctgtcagcgacgcg cccaagcttttaaaaatgcctcttcatgtgtaaggc 
 
 
 
T able 2.2. Primers used for RT-PCR and/or qRT-PCR. 
 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
ATF3 gtttgaggattttgctaacctgac agctgcaatcttatttctttctcgt 
DKK-1 catcagactgtgcctcagga  ggcaagacagaccttctcca 
Egr-1 ctgcgacatctgtggaagaa tgtcctgggagaaaaggttg 
HO-1 atgacaccaaggaccagagc gtgtaaggacccatcggaga 
KLF4 cgaattctatggctgtcagcgacgcg cccaagcttttaaaaatgcctcttcatgtgtaaggc 
NAG-1 acgctacgaggacctgctaa agattctgccagcagttggt 
Nur77 cacagcttgcttgtcgatgt tcttgtcaatgatgggtgga 
PDE4B ataccgatcgcattcaggtc agtggtggtgagggactttg 
GAPDH tcaacggatttggtcgtatt ctgtggtcatgagtccttcc 
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2.5. RNA Stability 
 HCT-116 cells were grown to 60% to 80% confluence and pretreated with DMSO or 
resveratrol (50 μM) for 24 h in serum-free media.  After pretreatment, actinomycin D was 
added directly to the media at a dose of 5 M to terminate transcription as indicated.  Total 
RNA was isolated and reverse transcribed.  Reverse transcription PCR (RT-PCR) for ATF3 
and GAPDH occurred as previously described. 
 
2.6. Western Blot Analysis 
 Cells were grown to 60% to 80% confluence in 60 mm plates.  For transient 
transfections, plasmid mixtures containing 2.5 μg of Egr-1 WT or aDaa expression vector 
were transfected for 5 h in serum-free media as described.  Cells were serum starved 
overnight and treated with resveratrol and/or trichostatin A (TSA) as indicated in serum-free 
media.  Protein lysates were isolated in ice-cold RIPA buffer (PBS, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with protease (1 mM PMSF, 1 μg/mL aprotinin, and 
1 μg/mL leupeptin) and phosphatase (0.1 nM Na3VO4 and 25 mM NaF) inhibitors.  Protein 
concentrations were measured using BCA protein assay (Thermo Fisher Scientific) with 
bovine serum albumin as the standard.  Total protein was subjected to Western blot analysis 
as described 
(156)
.  Briefly, proteins (30 μg or 50 μg) were separated by SDS-PAGE (8-12%) 
and transferred to nitrocellulose membrane (Pall Life Sciences, Pensacola, FL).  Membranes 
were blocked in 5% skim milk in TBS/0.05% Tween-20 (TBS-T) for 1 h and incubated with 
specified antibodies at 4 C overnight.  After three washes with TBS-T, blots were incubated 
with horseradish peroxidase-conjugated secondary antibody for 1 h and washed three times.  
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Protein signal was detected using Enhanced ChemiLuminescence System (Thermo Fisher 
Scientific). 
 
2.7. de novo Protein Synthesis 
 HCT-116 cells were grown to 60% to 80% confluence in 60 mm plates and pretreated 
with CHX (10 mg/mL) for 30 min in serum-free media.  After pretreatment, DMSO or 
resveratrol (50 μM) was added directly to the media and incubated for 24 h.  Total RNA was 
isolated and reverse transcribed.  Quantitative RT-PCR for ATF3 and GAPDH occurred as 
described.   
 
2.8. Transfection using Luciferase Reporter System 
 Transient transfections were performed using LipofectAMINE (Invitrogen, Carlsbad, 
CA) according to manufacturer’s protocol.  HCT-116 cells were seeded in 12-well plates at a 
concentration of 2.0 x 10
5
 cells per well.  The next day, plasmid mixtures containing ATF3 
promoter (0.5 μg) and pRL-null vector (0.05 μg) were co-transfected for 5 h in serum-free 
media.  For co-transfection experiments, 0.25 μg of the ATF3 promoter and 0.25 μg of 
expression vector were co-transfected with 0.05 μg pRL-null vector.  For competition assays, 
plasmid mixtures were prepared as indicated in Figure A.9.  To measure Egr-1 and NAG-1 
activity, plasmid mixtures containing pEBS1
4
luc (0.375 μg) and Egr-1 or SIRT1 expression 
vector (0.375 μg or 0.25 μg) were co-transfected with 0.0075 μg pRL-null vector, as 
indicated in Figures B.1 and B.4, using PolyJet DNA in vitro Transfection Reagent 
(SignaGen Laboratories, Rockville, MD). After transfection, cells were treated with 
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resveratrol (50 μM) in serum-free media for 24 h.  Cells were harvested in 1X passive lysis 
buffer, and luciferase activity was measured and normalized to pRL-null luciferase activity 
using DualGlo Luciferase Assay Kit (Promega). 
 
2.9. RNA Interference 
 Egr-1 sense and antisense oligonucleotides were previously described 
(156)
.  ATF3 and 
KLF4 siRNA were purchased from Santa Cruz Biotechnology; control siRNA was purchased 
from Ambion (Austin, TX).  HCT-116 cells were transfected with either 100 nM (ATF3 and 
KLF4) or 200 nM (Egr-1) of each construct using TransIT-TKO transfection reagent (Mirus, 
Madison, WI).  After transfection for 24 h, cells were serum starved overnight and treated as 
indicated in Figure A.5.  Total protein was subjected to Western blot analysis as described.  
 
2.10. Electrophoretic Mobility Shift Assay (EMSA) 
 HCT-116 cells were grown to 80% confluence.  After overnight serum starvation, 
cells were treated with resveratrol (50 μM) for 24 h.  Cells were then washed with PBS and 
nuclear extracts were prepared using Nuclear Extract Kit (Active Motif, Carlsbad, CA) 
according to protocol.  Double-stranded oligonucleotides corresponding to (F, 5’-
GTGAGCGAGGGCGGGG-3’) and KLF4 (F, 5’-TCCACCCCTTCCACCCCT-3’) binding 
sites were synthesized and end-labeled with biotin (Operon, Huntsville, AL).  Mutant 
oligonucleotides of Egr-1 (F, 5’-GTGAGCGAAAACGGGG-3’) and KLF4 (F, 5’-
TCCAAAACTTCCAAAACT-3’) were also synthesized.  To ensure specific binding of Egr-
1 and KLF4, recombinant proteins were generated using TNT Quick Coupled 
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Transcription/Translation System (Promega).  EMSA was done using the LightShift 
Chemiluminescent EMSA kit according to the manufacturer’s protocol (Thermo Fisher 
Scientific).  Briefly, biotin-labeled oligonucleotide (10 nM) was incubated with nuclear 
extract (5 μg) or recombinant protein and 1X binding buffer (Promega) at room temperature 
for 20 min.  For competition assay, proteins were pre-incubated with unlabeled 
oligonucleotide (10- or 100-fold) for 10 min. 
 
2.11. Chromatin Immunoprecipitation 
 HCT-116 cells were grown to 80% confluence and treated with resveratrol (50 μM).  
After 24 h, cells were fixed with 1% formaldehyde at 37 C for 10 min.  The fixed cells were 
scraped into conical tubes, pelleted, and lysed in lysis buffer containing protease and 
phosphatase inhibitors.  DNA was sheared into fragments by sonication 4 times at 10 s at 
50% constant maximal power.  The sonicated cell supernatant was diluted 10-fold in 
immunoprecipitation buffer and 1% of diluted cell supernatant was kept as a control (input).  
The chromatin was pre-cleared with protein A/G agarose, 20 μg heat-denatured salmon 
sperm DNA, 50 μg bovine serum albumin, and 10 μg antibodies against Egr-1, KLF4, or IgG 
overnight at 4 C.  The immunocomplexes were washed five times with wash buffer and 
eluted with elution buffer.  Protein-DNA cross-links were reversed with 27 μL of 5 M NaCl 
and 1 μL of 10 mg/mL RNAse A at 65 C for 4 h and incubated with 2 μL of 20 mg/mL 
proteinase K at 45 C for 1 h.  The DNA was purified by phenol extraction and ethanol 
precipitation.  The region between -298 and -114 bp of the human ATF3 promoter was 
amplified by qRT-PCR and RT-PCR using F, 5’-CGGCTCCGGTCCTGATATGG-3’ and R, 
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5’-AGAACCGGCCGAACGGAGCG-3’ as described.  For NAG-1, the region between -133 
and +41 bp of the promoter was amplified using F, 5’-CCAGAAATGTGCCCTAGCTT-3’ 
and R, 5’-GACCGGGACTGACCAGATG-3’.  The 184 bp (ATF3) or 202 bp (NAG-1) 
product was resolved on 2% agarose gel and visualized under ultraviolet light. 
 
2.12. Mammalian 2-Hybrid Assay 
 The pM/Egr-1 and pVP16/KLF4 vectors for mammalian-2-hybrid were generated.  
PCR fragments were amplified from pcDNA3.1/NEO/Egr-1 and pcDNA3.1/His/V5/KLF4 
using Egr-1 and KLF4-specific primers, respectively (see Table 2.1).  After PCR, fragments 
were cloned into pCR2.1/TOPO vector (Invitrogen), digested with EcoRI and HindIII 
restriction enzymes, and cloned into pM or pVP16 vectors.  Deletion clones of pM/Egr-1 
were generated as described using del AD and del ZD2 primers (Table 2.1).  Mammalian-2-
hybrid assay was performed according to Matchmaker Mammalian Assay Kit 2 protocol 
(Clontech, Mountain View, CA).  Transfection with LipofectAMINE occurred as described 
using plasmid mixtures containing 0.2 μg of pM/Egr-1 or deletion construct, 0.2 μg of 
pVP16/KLF4, 0.2 μg of pG5Luc, and 0.06 μg pRL-null vector. 
 
2.13. Immunoprecipitation 
 For immunoprecipitation of Egr-1 (WT and deletions, generated as described) and 
KLF4, each expression vector was transfected into HCT-116 cells as indicated and grown to 
confluence (see Figure A.11).  For acetylation experiments, Egr-1 WT or aDaa mutation 
expression vector was transfected into HCT-116 cells.  Cells were then serum starved 
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overnight and treated with resveratrol (50 μM) for 2 h.  After washing with ice-cold PBS, 
cells were harvested in RIPA buffer containing inhibitors and incubated on ice for 30 min.  
Cell suspensions were centrifuged for 10 min, supernatant collected, and protein 
concentrations were measured.  Approximately 600 μg of protein and 5 μg of antibody (IgG, 
Egr-1or KLF4) were incubated overnight at 4°C with shaking.  The following day, lysate-
antibody mix was added to 50 μL protein A/G resin beads (Santa Cruz Biotechnology), 
which was washed and re-suspended in RIPA buffer, and incubated overnight at 4°C with 
shaking.  After overnight incubation, samples were centrifuged for 30 s and the supernatant 
removed.  Protein A/G resin beads were washed 5 times with 500 μL ice-cold PBS, with 
complete removal of PBS after each wash to prevent background.  After the last wash, 60 μL 
of 2X loading buffer was added to the resin beads, vortexed vigorously, and boiled at 100ºC 
for 5 min to denature and separate the protein from the beads.  Samples were then 
centrifuged, supernatant collected, and Western blot analysis was performed using 10 μL of 
sample as described.       
 
2.14. Caspase 3/7 Enzymatic Activity 
 Apoptosis was measured using Apo-ONE Homogenous Caspase-Glo-3/7 Assay kit 
(Promega) according to manufacturer’s protocol.  Cells were harvested in RIPA buffer 
containing protease and phosphatase inhibitors.  The same volume of Caspase-Glo-3/7 
reagent was added to cell lysates (30 μg protein) in 96-well plates and incubated at room 
temperature in the dark for 1 h.  Luminescence was measured using FLX800 microplate 
reader (BioTek, Winooski, VT).   
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2.15. Statistical Analyses 
 SAS for Windows (v9.2; SAS Institute, Inc., Cary, NC) statistical analysis software 
was used.  For multiple group comparisons, analysis of variance with Tukey’s multiple 
comparison test was used to compare mean values.  The Student’s t test was used to analyze 
differences between samples.  Results were considered statistically significant at *P <0.05, 
**P <0.01, ***P <0.001.    
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This chapter is revised based on the article published by Whitlock et al.: 
 
 Whitlock NC, Bahn JH, Lee SH, Eling TE, and Baek SJ (2011). Resveratrol-induced 
apoptosis is mediated by early growth response-1, Krüppel-like factor 4, and activating 
transcription factor 3.  Cancer Prevention Research 4(1): 116-127. 
 
My contributions to this work include: (1) experimental design, (2) acquisition, analysis, and 
interpretation of data, (3) gathering and reviewing the literature, (4) creating figures/tables, 
and (5) drafting and revising the article.  JBH generated the KLF4 and pVP16/KLF4 
constructs.  SHL performed ATF3 promoter assay with Egr-1 overexpression.  All authors 
reviewed and approved the final version for publication.   
 
 
 
 
 
3.1. Abstract 
 Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess 
anti-tumorigenic properties in several cancers, including colorectal cancer.  However, the 
underlying mechanism(s) involved is not completely understood.  In the present study, we 
investigated the effect of resveratrol treatment on gene modulation in human colorectal 
cancer cells and identified activating transcription factor 3 (ATF3) as the most highly 
induced gene after treatment.  We confirmed that resveratrol up-regulates ATF3 expression, 
both at the mRNA and protein level, and showed resveratrol involvement in ATF3 
transcriptional regulation.  Analysis of the ATF3 promoter revealed the importance of early 
growth response-1 (Egr-1; located at -245 to -236) and Krüppel-like factor 4 (KLF4; located 
at -178 to -174) putative binding sites in resveratrol-mediated ATF3 transactivation.  
Specificity of these sites to the Egr-1 and KLF4 protein was confirmed by electrophoretic 
mobility shift and chromatin immunoprecipitation assays.  Resveratrol increased Egr-1 and 
KLF4 expression, which preceded ATF3 expression, and further suggests Egr-1 and KLF4 
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involvement in resveratrol-mediated activity.  We provide evidence for Egr-1 and KLF4 
interaction in the presence of resveratrol, which may facilitate ATF3 transcriptional 
regulation by this compound.  Furthermore, we demonstrate that induction of apoptosis by 
resveratrol is mediated, in part, by increased ATF3 expression.  Taken together, these results 
provide a novel mechanism by which resveratrol induces ATF3 expression and represent an 
additional explanation of how resveratrol exerts its anti-tumorigenic effects in human 
colorectal cancer cells.    
 
3.2. Introduction 
 Current research suggests that various dietary phytochemicals function as 
chemopreventive and/or adjuvant chemotherapeutic agents, adding to the paradigm that a diet 
high in fruit and vegetable content confers protection against chronic disease 
(3)
.  One such 
phytochemical is resveratrol (3, 4’, 5-trihydroxystilbene), a naturally occurring phytoalexin 
readily available in the diet and to which a plethora of health-promoting effects have been 
ascribed 
(4)
.  Resveratrol has elicited much attention as a potential anticancer agent since the 
inhibitory effect of this compound on carcinogenic processes was first reported in 1997 
(5)
.  
Subsequently, numerous studies have illustrated the anti-proliferative effect of resveratrol on 
cancer cells, which is believed attributable to induction of cell cycle arrest in the G1/S or 
G2/M phase and induction of apoptosis and related proteins 
(44, 45)
.  More importantly, 
treatment with resveratrol inhibited tumorigenesis in vivo 
(7, 82, 159)
.  However, the underlying 
mechanism(s) involved in the anti-tumorigenic/anti-carcinogenic activities of resveratrol 
remain poorly defined due to its capacity to modulate a multitude of signaling pathways. 
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Activating transcription factor 3 (ATF3), a member of the ATF/CREB family of bZIP 
transcription factors, is characterized as a stress-inducible or adaptive response gene 
(121)
.  
Much controversy exists as to the physiological role of ATF3 in tumorigenesis, and ATF3 is 
demonstrated to a positive and/or negative modulator of tumor progression.  Recently, a 
dichotomous role was reported for ATF3 in cancer development; the authors concluded its 
role as a tumor suppressor or oncogene is largely dependent on cellular context and extent of 
malignancy 
(122)
.  However, several lines of evidence suggest that ATF3 may function as a 
tumor suppressor gene in colorectal carcinogenesis.  Firstly, ATF3 expression is markedly 
reduced in cancer tissues, including colon, when compared to normal adjacent tissue 
(160, 161)
.  
Secondly, ATF3 overexpression is demonstrated to elicit a number of cellular responses.  
These include (1) the induction of cell cycle arrest with concomitant inhibition of 
proliferation 
(162)
, (2) induction of apoptosis in vitro and in vivo 
(155, 163-165)
, inhibition of 
invasion and associated genes 
(166-168)
, and retardation of tumor formation in vivo 
(163, 168)
.  
Finally, ATF3 is reported to mediate or enhance induction of apoptosis by compounds 
demonstrated to possess antitumor and anticancer properties 
(130, 155, 169-171)
.  Thus, it is 
believed that ATF3 plays an anti-tumorigenic and anti-carcinogenic role in colorectal cancer.   
In the study described here, we examined the effect of resveratrol treatment on gene 
modulation in HCT-116 human colorectal cancer cells.  We identified ATF3 as the most 
highly induced gene after treatment and sought to investigate the transcriptional mechanism 
and biological consequence of ATF3 expression in response to resveratrol.  Here, we report 
that early growth response-1 (Egr-1) and Krüppel-like factor 4 (KLF4) mediates ATF3 
transactivation by resveratrol.  We show Egr-1 and KFL4 interaction in the presence of 
 
 47 
resveratrol, which may facilitate ATF3 transcriptional regulation by this compound.  
Furthermore, we demonstrate induction of apoptosis by resveratrol is mediated, at least in 
part, by ATF3. 
 
3.3. Results 
3.3.1. Effect of Resveratrol on Gene Expression in HCT-116 Cancer Cells 
 The mechanism(s) underlying the anti-tumorigenic properties of resveratrol in 
colorectal cancer remain mostly unclear.  To investigate how resveratrol alters gene 
expression in colorectal cancer cells, microarray analysis was performed using HCT-116 
cells treated with resveratrol (100 μM).  Among the genes up-regulated by the treatment, 
ATF3 was identified as most highly induced (Table 3.1).  We confirmed resveratrol-induced 
ATF3 transcript using reverse transcription PCR (Figure A.1).  The alteration of mRNA 
transcripts of five additional genes (HO-1, DKK1, NAG-1, Nur77, and PDE4B) by resveratrol 
was also confirmed, each of which are suggested to play a role in tumorigenesis 
(172-176)
.   
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Table 3.1. Alteration of gene expression profiles of HCT-116 colorectal cancer cells by 
resveratrol (100 μM).  HCT-116 human colorectal cancer cells were treated with resveratrol 
(100 μM) for 24 h and microarray analysis was performed.  The top 13 up- and down-
regulated genes are listed.   
 
Gene Symbol Gene Name Accession No. Fold 
Change 
ATF3 Activating transcription factor 3 I_929428 20.37 
 
MTHFD2 
Methylenetetrahydrofolate (NAD-dependent) 2, 
Methenyltetrahydrofolate cyclohydrolase 
 
I_939586 
 
13.57 
HMOX1 Heme oxygenase 1 (HO-1) I_961390 13.13 
PLAB Macrophage inhibitory cytokine 1 (NAG-1) I_966585 12.59 
ASNS Asparagine synthase I_930098 10.56 
S100A2 Homo sapiens S100 calcium binding protein A2, 
mRNA 
NM_005978.2 9.88 
 
C20orf97 
Protein with high similarity to neuronal cell death 
Inducible Putative Kinase 
 
I_961961 
 
8.93 
SULF2 Member of the sulfatase family I_962934 8.23 
CNK Cytokine inducible kinase I_964814 7.80 
FUS RNA-binding protein FUS I_965527 7.78 
DKK1 Dickkopf homolog 1 I_932501 7.47 
 
HERPUD1 
Homocysteine-inducible endoplasmic reticulum stress-
inducible ubiquitin-like domain member 1 
 
I_959712 
 
7.16 
NR4A1 Nuclear receptor subfamily 4 group A member 1 
(Nur77) 
I_932430 7.13 
 
NR2F1 
Homo sapiens nuclear receptor subfamily 2, group F, 
member 1 (NR2F1), mRNA 
 
NM_005654.2 
 
-3.46 
HNRPA2B1 Heterogenous nuclear ribonucleoprotein A2/B1 I_930777 -3.47 
 
HMGA2 
High-mobility group (nonhistone chromosomal) 
protein isoform I-C 
 
I_963472 
 
-3.48 
 
HAIK2 
Member of the intermediate filament family, has 
moderate similarity to keratin 19 (human KRT19) 
 
I_958778 
 
-3.65 
PRKACB cAMP dependent protein kinase catalytic subunit beta I_931783 -3.69 
WNT16 Wingless-type MMTV integration site family member 
16 
I_929920 -3.77 
PDE4B Phosphodiesterase 4B I_929286 -3.79 
SCG2 Secretogranin II (chromogranin C) I_928496 -3.81 
 
GPR110  
Member of the secretin family of G protein-coupled 
receptors 
 
I_957588 
 
-3.98 
VSNL1 Visinin-like Protein 1 I_940805 -4.16 
 
DKFZP434P1735 
Protein containing 10 armadillo/beta-catenin repeats, 
weak similarity to S. cerevisiae Vac8p 
 
I_931567 
 
-4.26 
CPO Coproporphyrinogen oxidase I_956835 -4.54 
KITLG Stem cell factor, ligand of KIT tyrosine kinase receptor I_944208 -5.04 
 
 
 
 49 
3.3.2. Resveratrol Increases ATF3 Expression in Cancer Cells 
 We next determined whether resveratrol increases ATF3 expression at the protein 
level.  As shown in Figure A.2A and A.2B, resveratrol increased ATF3 in a concentration- 
and time-dependent manner in HCT-116 cells.  Furthermore, increased ATF3 expression was 
observed in both colorectal (Figure A.2C) and non-colorectal (Figure A.2D) cancer cells 
after treatment; however, we did not observe ATF3 induction in LoVo colorectal and 
SqCC/Y1 head and neck cancer cells.  Absence of ATF3 induction by resveratrol in these 
cells is most likely due to high endogenous expression of ATF3 (LoVo) or the lack of proper 
signaling pathway(s) needed for ATF3 increase by resveratrol (SqCC/Y1).  Because 
resveratrol increased ATF3 expression at the mRNA and protein level, we sought to 
characterize ATF3 as a molecular target of this compound at the transcription level. 
 
3.3.3. Egr-1 and KLF4 are involved in Resveratrol-Induced ATF3 Expression 
 To identify the transcriptional binding site(s) responsible for resveratrol-mediated 
ATF3 expression, HCT-116 cells were transfected with different promoter constructs 
spanning the -1850 to +34 bp promoter region (Figure A.3A).  Resveratrol treatment resulted 
in a significant increase in ATF3 promoter activity for all reporter constructs; however, the 
greatest induction was observed within the -514 and +34 bp region, suggesting that a major 
response element(s) may be present.  This region was further analyzed using three 
independent transcription factor search engines (Genomatix-MatInspector, TFSearch, and 
Transcription Element Search System) and five possible factors were commonly identified: 
p53, Sp1, Egr-1, KLF4, and ATF/CREB (Figure A.3B). 
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To investigate the role of identified cis-acting elements in resveratrol-mediated 
transcriptional regulation of ATF3, co-transfection experiments were performed utilizing 
expression vectors of the aforementioned factors and ATF3 promoter constructs as indicated 
(Figure A.4).  Expression of each vector, with the exception of ATF3, resulted in increased 
pATF3 -514/+34 luciferase activity after resveratrol treatment compared to pcDNA3.1 empty 
vector control (Figure A.4A).  Interestingly, cells over-expressing KLF4 and Egr-1showed 
the greatest increase in resveratrol-induced ATF3 promoter activity, resulting in a 4.1- and 
4.3-fold induction, respectively.  A similar pattern was observed for the -132 to +34 bp 
region (Figure A.4B); however, co-transfection of these expression vectors with pATF3 -
84/+34 reporter construct had no effect on promoter activity after treatment (Figure A.4C).  
Of note, suppression of ATF3 promoter was observed in cells with ATF3 overexpression, 
consistent with its role as a negative self-regulator 
(177)
.  These results identify putative 
resveratrol response elements located within the -514 and -84 bp region of the ATF3 
promoter and suggest that both Egr-1 and KLF4 may play a role in ATF3 regulation by 
resveratrol.   
 To clarify the importance of Egr-1 and KLF4 in resveratrol-mediated activation of 
ATF3, internal deletion clones lacking the Egr-1 and KLF4 binding sites were generated and 
transfected into HCT-116 cells.  Deletion of Egr-1 or KLF4-A binding site markedly reduced 
ATF3 promoter activity in response to resveratrol treatment when compared to wild type 
(Figure A.5A).  Deletion of the KLF4-B binding site did not change resveratrol-induced 
transactivation.  Furthermore, because deletion of binding sites corresponding to either Egr-1 
or KLF4-A resulted in a significant decrease in resveratrol-induced promoter activity, a 
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deletion clone lacking both these sites was generated.  Resveratrol-induced activity was 
dramatically reduced in cells transfected with the double deletion promoter construct 
compared to wild type (Figure A.5A).  Moreover, suppression of either endogenous Egr-1 or 
KLF4 decreased ATF3 expression in the presence of resveratrol (Figure A.5B), confirming 
that both Egr-1 and KLF4 contribute to resveratrol-induced ATF3 expression. 
 
3.3.4. Egr-1 and KLF4 bind to the ATF3 Promoter 
 To determine whether Egr-1 and KLF4 bind to the ATF3 promoter, EMSA was 
performed using biotin-labeled oligonucleotides containing 1-2 copies of the corresponding 
promoter binding site.  First, we examined the effect of resveratrol on promoter binding by 
these factors using nuclear extracts prepared as described in Chapter 2.  Pre-incubation of 
resveratrol-treated nuclear extracts with Egr-1 and KLF4 oligonucleotides resulted in 
DNA/protein complex formation that was competed out with addition of 10X and 100X 
molar excess of unlabeled wild type oligonucleotides (Figure A.6, left, lanes 3-4), whereas 
pre-incubation with unlabeled mutant oligonucleotides had no affect on DNA/protein 
complex formation (Figure A.6, left, lanes 5-6).  This suggests that both Egr-1 and KLF4 are 
able to bind to the ATF3 promoter.  Secondly, we verified the specificity of the binding sites 
for Egr-1 and KLF4 using in vitro translated proteins mixed with their respective 
oligonucleotides.  As shown in Figure A.6, both Egr-1 and KLF4 bind to their specific 
binding sites as evidenced by the formation of shift bands that were competed out by 10X 
and 100X molar excesses of unlabeled oligonucleotides (Figure A.6, right, lanes 10-11).  
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Addition of mutant oligonucleotides did not affect binding of Egr-1 or KLF4 to the ATF3 
promoter (Figure A.6, left, lanes 12-13).   
 Finally, a chromatin immunoprecipitation (ChIP) assay was performed to further 
confirm that Egr-1 and KLF4 bind to the ATF3 promoter after resveratrol treatment.  As 
shown in Figure A.7, immunoprecipitation of the chromatin/protein complex with Egr-1 and 
KLF4 resulted in the enrichment of these proteins at the ATF3 promoter (left) and the 
visualization of a 184 bp band of the amplified promoter (right).  In conjunction with results 
described above, these data suggest that both Egr-1 and KLF4 bind to the ATF3 promoter and 
activate transcription in the presence of resveratrol.  However, Egr-1 may contribute more to 
resveratrol-induced ATF3 expression, since resveratrol enhances Egr-1 binding capacity to 
the ATF3 promoter. 
 
3.3.5. de novo Synthesis is required to Increase ATF3 Expression 
 We then examined the requirement of de novo protein synthesis for resveratrol-
mediated ATF3 expression because Egr-1 and KLF4 appear to be required for induction of 
ATF3.  HCT-116 cells were treated with CHX and resveratrol (50 μM).  In the presence of 
CHX, resveratrol was unable to increase ATF3 expression, suggesting that ATF3 increase by 
resveratrol is dependent on de novo protein synthesis (Figure A.8A).  We next determined 
whether resveratrol could alter expression of Egr-1 and KLF4.  Resveratrol treatment 
increased Egr-1 and KLF4 mRNA transcript (Figure A.8B) and protein expression (Figure 
A.8C).  It should be noted that induction of both Egr-1 and KLF4, which occurred at 
approximately 1 h of treatment and continued until 3 h, preceded that of ATF3, which began 
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after 6 h.  Together, these results are compatible with the notion that observed increase in 
ATF3 expression by resveratrol requires synthesis of Egr-1 and KLF4. 
 
3.3.6. Egr-1 and KLF4 Interaction Facilitates Resveratrol-Mediated ATF3 Induction 
 Because both Egr-1 and KLF4 are involved in resveratrol-mediated activity, we 
examined whether these factors coordinate or compete in ATF3 expression.  HCT-116 cells 
were co-transfected with pATF3 -514/+34 and expression vectors and treated as described.  
As observed previously, both Egr-1 and KLF4 increased ATF3 promoter activity in the 
presence of resveratrol (Figure A.9).  Moreover, co-expression of these factors resulted in 
enhanced transactivation of ATF3 at both the basal level and after resveratrol treatment. 
 Previous studies have shown interaction between two Zn finger transcription factors 
(178)
 and that this interaction facilitates transcriptional activation 
(179)
.  To investigate the 
potential for Egr-1 and KLF4 interaction, mammalian-2-hybrid assay was performed.  
Briefly, Egr-1 and KLF4 were cloned into the pM vector containing a DNA binding domain 
and pVP16 vector containing an activation domain, respectively.  These constructs were then 
co-transfected with the luciferase reporter construct pG5Luc into HCT-116 cells and treated 
with resveratrol.  If there is interaction, luciferase activity should be detected resulting from 
the formation of a complex between the two vectors and subsequent binding to the DNA 
binding domain of the pG5Luc vector; this results in pG5Luc promoter activation.   
 As shown in Figure A.10A, Egr-1 and KLF4 bind to each other at the basal level and 
this interaction is enhanced after resveratrol treatment (7.2-fold vs. 52-fold increase).  
Increased Egr-1 and KLF4 interaction was also observed after DIM treatment.  DIM 
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increases ATF3 expression 
(130)
.  To exclude the potential for direct binding of pVP16/KLF4 
to the DNA binding domain of the pM empty vector, the vectors were co-transfected and 
mammalian-2-hybrid assay was performed; no interaction was detected, allowing one to infer 
the interaction of Egr-1 and KLF4 is genuine (data not shown).   
 We next sought to tentatively identify the region that may facilitate this interaction 
and generated pM/Egr-1 deletion constructs lacking (1) 133-159 aa of the activation domain 
and (2) 370-395 aa of the Zn finger domain (Figure A.10B, top).  Both the partial deletion of 
the activation domain and deletion of the second Zn finger domain of Egr-1 resulted in 
decreased interaction with KLF4 (Figure A.10B, bottom).  We confirmed mammalian-2-
hybrid assay by Egr-1 and KLF4 immunoprecipitation experiments (Figure A.11).  Egr-1 
and KLF4 are co-immunoprecipitated with either antibody, whereas Egr-1 deletion clones 
had diminished binding capacity to KLF4.  Together, these data suggest that Egr-1 and KLF4 
physically interact, which is increased by resveratrol, and that the Egr-1 activation or Zn 
finger domain may mediate this interaction. 
 
3.3.7. Knockdown of ATF3 Suppresses Resveratrol-Induced Apoptosis 
 We have identified ATF3 as a molecular target of resveratrol; however, the biological 
consequence(s) of ATF3 induction by resveratrol in colorectal tumorigenesis is unknown.  
As described in the introduction, pharmaceuticals and phytochemicals’ increase of ATF3 
mediated or enhanced apoptosis by these compounds 
(130, 155, 169-171)
.  To determine if this is 
true for resveratrol, we measured caspase-3/7 enzyme activity for resveratrol-treated HCT-
116 and HT29 cancer cells.  As depicted in Figure A.12A, resveratrol treatment increased 
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apoptosis in a dose-dependent manner.  Furthermore, ATF3 overexpression in these cells also 
increased apoptosis, which depend on caspase activation (Figure A.12B).  Together, these 
data suggest that both resveratrol and ATF3 expression induce apoptosis in our model 
system.  Next, to investigate whether resveratrol-induced apoptosis is mediated by ATF3, 
ATF3 expression was knocked down by siRNA followed by resveratrol treatment for 24 h.  
As depicted in Figure A.12C, knockdown of ATF3 significantly abrogated caspse-3/7 
enzymatic activity by resveratrol.  This suggests that ATF3 plays a role in resveratrol-
induced apoptosis. 
 
3.3.8. Egr-1 and KLF4 Transactivate ATF3 Independent of Resveratrol 
 Results herein suggest Egr-1 and KLF4 involvement in resveratrol-mediated ATF3 
activation.  To determine if these transcription factors are able to affect ATF3 transcription 
individually, promoter activity was measured after co-transfection with Egr-1 or KLF4 
expression vectors.  As shown in Figure A.13, both Egr-1 and KLF4 are able to increase 
ATF3 promoter activity.  Of note, the minimum region required for Egr-1 or KLF4-mediated 
induction may be independent of that shown to be required for resveratrol (see Figure A.4).  
For Egr-1, the -1850 bp of the ATF3 promoter showed the highest luciferase activity and for 
KLF4, this region lies within the -1420 bp of the ATF3 promoter.  This result suggests that 
binding sites of Egr-1 and KLF4 within the -514 bp of the ATF3 promoter play an important 
role in resveratrol-induced ATF3 expression; however, Egr-1 and KLF4 also increase ATF3 
promoter activity in the absence of resveratrol through different promoter regions.  
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3.3.9. Posttranscriptional Regulation of ATF3 by Resveratrol as an Alternate Regulatory 
Pathway 
 Posttranscriptional control of eukaryotic gene expression provides an alternative 
regulatory process(s) to control protein abundance 
(180)
.  To determine if such processes 
account for ATF3 regulation by resveratrol, ATF3 mRNA stability was measured as 
described in Chapter 2.  Briefly, HCT-116 cells were pre-treated with resveratrol (50 μM) 
for 24 h followed by actinomycin D, to terminate transcription, for the indicated times.  As 
depicted in figure A.14, resveratrol stabilized ATF3 mRNA and increased the half-life from 
approximately 7 h to 14 h, suggesting that posttranscriptional control of ATF3 by resveratrol 
may account for the observed increase in ATF3 protein level.    
 
3.4. Discussion 
 Resveratrol, a dietary phytoalexin readily available in the diet, has garnered much 
attention as a potential chemopreventive and/or chemotherapeutic agent.  Numerous studies, 
utilizing in vitro and in vivo model systems, have illustrated resveratrol’s capacity to inhibit 
the stages of carcinogenesis (initiation, promotion, and progression) and modulate a 
multitude of signaling pathways associated with cellular growth and division, apoptosis, 
angiogenesis, and metastasis 
(6)
.  However, the underlying mechanism(s) involved in the anti-
tumorigenic/anti-carcinogenic activities of resveratrol, especially in colorectal cancer, are 
complex and remain poorly defined.  The present study sought to investigate the effect of 
resveratrol on gene modulation in HCT-116 human colorectal cancer cells in order to identify 
a novel target that may mediate the anticancer activities of this compound and determine the 
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mechanism involved in its regulation.  Our data identified ATF3 as the most highly 
expressed gene after resveratrol treatment (Table 3.1) and showed ATF3 was indeed up-
regulated at both the mRNA (Figure A.1) and protein (Figure A.2) level by the compound.  
We also demonstrate increased stability of the ATF3 transcript by resveratrol, which may 
contribute to the observed ATF3 expression in colorectal cancer cells highly induced by 
resveratrol (Figure A.14).     
 Recently, a dichotomous role in cancer development was reported for ATF3; the 
authors of that study demonstrated both a tumor suppressive (early-stage tumorigenesis) and 
oncogenic (late-stage tumorigenesis) role in breast cancer cell lines derived from similar 
genetic backgrounds with varying degrees of malignancy 
(122)
.  Similarly, a duality of 
function was demonstrated for ATF3 in cancer studies of the prostate 
(164, 181)
 and of the colon 
(168, 182)
.  Yet, as described in the introduction, several lines of evidence suggest ATF3 
behaves as a negative regulator of tumorigenesis.  For example, ATF3 expression is induced 
by several compounds demonstrated to possess anti-tumorigenic properties 
(130, 155, 169-171)
.  
The results presented here add to the list of compounds that induce ATF3 with mechanistic 
data. 
 To elucidate the molecular mechanism by which resveratrol induced ATF3 
expression, the promoter region spanning -1850 to +34 bp was assessed by luciferase assay 
in response to resveratrol.  We found that resveratrol transactivated the ATF3 promoter and 
identified putative response elements located within the -514 to -84 bp (Figure A.3).  Co-
transfection experiments suggested the involvement of the transcription factors Egr-1 and 
KLF4 (Figure A.4).  Egr-1 and KLF4 participation in resveratrol-mediated activation of 
 
 58 
ATF3 was confirmed by deletion (Figure A.5A) and knockdown (Figure A.5B) 
experiments.  Interestingly, deletion of both Egr-1 and KLF4-A binding sites from the ATF3 
promoter dramatically reduced transactivation by resveratrol, indicating that the combination 
of these two factors is important for ATF3 transcriptional regulation by resveratrol.  Yet, we 
cannot exclude the involvement of other cofactors, such as p53 and Sp1 (Figure A.4), in the 
compound’s-mediated activity.  ATF3 regulation by p53 is documented in the literature 
(183)
 
and p53 is increased by resveratrol 
(139)
, which suggests a potential role for p53 in resveratrol-
mediated ATF3 activation.  Furthermore, Sp1 was recently demonstrated to regulate ATF3 
expression in colon cancers cells 
(184)
; however, we did not observe Sp1 induction by 
resveratrol (data not shown).  Here, we focused on Egr-1 and KLF4 because both increased 
resveratrol-mediated ATF3 activation and were modulated by the compound.  In addition, as 
shown in Figure A.13, both Egr-1 and KLF4 activate ATF3 promoter activity in the absence 
of resveratrol, indicating the pleiotropic role of both Egr-1 and KLF4 in ATF3 transcriptional 
regulation.  Because resveratrol can increase Egr-1 and KLF4 expression and transcription 
activity, one could speculate that observed anticancer properties of resveratrol may be 
facilitated through either an Egr-1-mediated or KLF4-mediated mechanism.   
 Egr-1 and KLF4 belong to a family of immediate early response genes whose 
expression is transiently induced in response to various environmental stimuli 
(185, 186)
.  Each 
encode a transcription factor containing three carboxyl C2H2 type zinc finger motifs that 
coordinate the expression of genes associated with cell proliferation, differentiation, and 
apoptosis 
(186-188)
.  In addition, Egr-1 and KLF4 are suggested to act as master regulatory 
proteins involved in cell fate decisions 
(189, 190)
.  Nonetheless, as with ATF3, much 
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controversy exists as to the role of Egr-1 and KLF4 in cancer development and their 
biological function appears largely context dependent.  Several studies have demonstrated 
that Egr-1 and KLF4 expression facilitate tumor progression in vivo 
(191-194)
; however, there is 
ample evidence supporting a tumor suppressive role for both transcription factors 
(195-202)
.  
 Our data indicates that Egr-1 and KLF4 are able to bind to the ATF3 promoter 
(Figure A.6 and A.7) and that their biosynthesis is necessary for resveratrol-mediated 
activity (Figure A.8).  Moreover, these transcription factors cooperate in ATF3 
transactivation (Figure A.9).  From this, two inferences can be made: (1) synergism between 
Egr-1 and KLF4 promote ATF3 activation, which is enhanced after resveratrol treatment and 
(2) interaction between the two facilitate transcriptional regulation by ATF3 by the 
compound.  Indeed, the results ascertained by mammalian 2-hydrid assay and 
immunoprecipitation experiments corroborate Egr-1 and KLF4 interaction (Figure A.10 and 
A.11, respectively).  Furthermore, resveratrol and DIM increased Egr-1 and KLF4 
interaction.  These results imply that a similar mechanism may contribute to induction of 
ATF3 by these and possibly other phytochemicals that increase ATF3 expression. 
 Current research suggests the importance of C2H2 type zinc finger domains in 
protein-protein interaction 
(203, 204)
.  Consistently, we found the zinc finger domain of Egr-1 
as a possible region responsible for interaction with KLF4.  Our data also identified the 
activation domain of Egr-1 as responsible for mediating the interaction with KLF4 (Figure 
A.10 and A.11).  To our knowledge, this is the first report identifying the involvement of the 
activation domain in protein-protein interaction of two zinc finger transcription factors.  
Thus, the activation domain contributes not only to the initiation of transcription but also 
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contribute to protein-protein interactions with other transcription factors; interaction via the 
activation domain or the zinc finger domain leads to enhanced compound-induced 
transcription.   
Results identify ATF3 as a molecular target of resveratrol whose regulation is 
mediated by Egr-1 and KLF4 interaction.  However, the biological consequence(s) of ATF3 
induction by the compound is unknown in colorectal tumorigenesis.  To answer this question, 
we examined induction of apoptosis by resveratrol and ATF3 in colorectal cancer cells 
because, as described, ATF3 mediates or enhances apoptosis by compounds with known 
antitumor activities.  As depicted in Figure A.12, resveratrol and ATF3 overexpression 
increased caspase 3/7 enzymatic activity in HCT-116 and HT29 cancer cells.  Furthermore, 
knockdown of ATF3 expression resulted in reduced apoptosis by resveratrol and suggests 
that ATF3 plays a role in resveratrol-induced apoptosis.  However, further study is required 
to determine whether ATF3 contributes to resveratrol anticancer effects in vivo.   
 In conclusion, we found the stress-inducible and/or adaptive response gene ATF3 as 
the most highly induced gene after resveratrol treatment in human colorectal cancer cells.  
Here, we report for the first time the involvement of resveratrol in the transcriptional 
regulation of ATF3 and that the C2H2 type zinc finger transcription factors Egr-1 and KLF4 
mediate this regulation.  We demonstrate that Egr-1 and KLF4 interact with each other in the 
presence of resveratrol, which may facilitate ATF3 transcriptional regulation by this 
compound.  Furthermore, increased ATF3 expression by resveratrol facilitates induction of 
apoptosis by the compound (Figure. 3.1). 
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Figure 3.1. Schematic diagram of ATF3-mediated resveratrol action in colorectal cancer cells.  
Egr-1 and KLF4 are involved in the induction of ATF3 by resveratrol.  Resveratrol increases the 
expression of both Egr-1 and KLF4; this in turn results in the interaction of Egr-1 with KLF4, 
potentially facilitated by the activation or zinc finger domain of Egr-1, leading to promoter binding 
and transactivation of ATF3.  Increased ATF3 expression results in increase of apoptosis in colorectal 
cancer cells.  Alternatively, both Egr-1 and KLF4 activate ATF3 promoter in the absence of 
resveratrol. 
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4.1. Abstract 
Resveratrol, a dietary phytochemical readily available in the diet, has elicited much 
attention as a potential chemopreventive and/or chemotherapeutic agent in several cancers, 
including colorectal cancer.  However, the underlying mechanism(s) involved is not 
completely understood.  Recently, we identified the transcription factor early growth 
response-1 (Egr-1) as a molecular target of resveratrol in colorectal cancer cells that is 
involved in resveratrol-mediated anticancer effects.  In the present study, we sought to 
investigate the role of the sirtuin 1 (SIRT1) deacetylase, which is suggested to account for the 
observed anticancer activities of resveratrol, in increased Egr-1 transcriptional activity by the 
phytochemical.  Here, we report a SIRT1-independent mechanism for resveratrol-induced 
Egr-1 activity due to decreased SIRT1 phosphorylation, resulting in suppression of SIRT1 
deacetylase activity.  We show that acetylation contributes to Egr-1-induced nonsteroidal 
anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) expression through increased 
Egr-1 binding to the NAG-1 promoter and enhanced transactivation.  Thus, acetylation of 
Egr-1 plays an important role in resveratrol-mediated transactivation of NAG-1.   Taken 
together, these results provide a novel mechanism by which resveratrol induces Egr-1 
transcriptional activity that is independent of SIRT1 expression.     
 
4.2. Introduction 
 Resveratrol (3, 4’, 5-trihydroxystilbene), a naturally occurring dietary phtyoalexin to 
which a plethora of health-promoting benefits have been ascribed 
(4)
, has elicited much 
attention as a potential cancer chemopreventive and/or chemotherapeutic agent since the 
 
 64 
inhibitory effect of the compound on carcinogenesis was first reported by Jang et al. 
(5)
.  
Subsequently, numerous studies have illustrated the anti-proliferative effect of resveratrol on 
cancer cells, which is attributable to induction of cell cycle arrest and/or apoptosis and 
related proteins 
(45, 69, 205)
.  Treatment with resveratrol has also been shown to result in 
induction of autophagocytosis and senescence in ovarian and colorectal cancer cells, 
respectively 
(61, 206)
.  Furthermore, resveratrol treatment resulted in the inhibition of 
angiogenic, invasive, and metastatic factor release 
(6)
 as well as inhibition of tumorigenesis in 
vivo 
(67, 159, 207)
.  However, the underlying mechanism(s) involved in the anticancer activities 
of resveratrol remain poorly defined. 
The seven member mammalian sirtuin family of histone deacetylases have gained 
considerable attention as novel targets for the treatment of chronic diseases, such as cancer 
(208)
.  Sirtuin 1 (SIRT1), a NAD-dependent type III histone and non-histone deacetylase, is 
reported to play a critical role in various physiological and pathological conditions, including 
carcinogenesis 
(208)
.  Yet, as to whether the inhibition or activation of SIRT1 contributes to 
the development of cancer is debatable due to its involvement in the inhibition of key tumor 
suppressor and proto-oncogene proteins 
(209)
.  In colorectal carcinogenesis, SIRT1 expression 
is demonstrated to inhibit tumor formation and proliferation in vitro and in vivo 
(210, 211)
.  
Moreover, resveratrol is identified as a potent activator of SIRT1 
(212)
 and activation of 
SIRT1 by resveratrol reduces tumorigenesis in vivo 
(213)
.  Furthermore, Boily et al. 
(214)
 
suggest that activation of the deacetylase by the phytoalexin is required, at least partially, for 
the observed anticancer activities of resveratrol. 
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 Previously, we identified the transcription factor early growth response-1 (Egr-1) as 
a molecular target of resveratrol in colorectal cancer cells and demonstrate Egr-1’s role in 
resveratrol-mediated activating transcription factor 3 (ATF3) activation and subsequent 
anticancer effects 
(215)
.  In the study described here, we sought to investigate the role of 
SIRT1 in increased Egr-1 transcriptional activity by the phytoalexin.  Here, we demonstrate a 
SIRT1-independent mechanism for resveratrol-induced Egr-1 activity and suggest the 
importance of acetylation, at least partially, in this response.  
 
4.3. Results  
4.3.1. Increased Egr-1 Activity by Resveratrol is SIRT1 Independent 
 Recently, Boily et al. 
(214)
 suggested that the anticancer effects of resveratrol are 
partially dependent on the presence of SIRT1 protein.  Thus, to investigate the role of SIRT1 
in resveratrol-induced Egr-1 transcriptional activity, we first examined the effect of 
resveratrol on SIRT1 phosphorylation status in HCT-116 human colorectal cancer cells.  
Current research suggests SIRT1 phosphorylation, particularly at serine residues 27 and 47, 
is associated with increased deacetylase activity 
(216-218)
.  As demonstrated in Figure B.1A 
and B.1B, resveratrol treatment did not alter total SIRT1 protein expression; however, we 
observed a dramatic decrease in SIRT1 phosphorylation at serine 27 but not serine 47, which 
occurred in a concentration- and time-dependent manner (Figure B.1A and B.1B, 
respectively).   
 Next, we determined if SIRT1 could affect resveratrol-induced Egr-1 transcriptional 
activity.  To accomplish this, we performed co-transfection experiments using the pEBS1
4
luc 
reporter construct, which contains four copies of the Egr-1 binding site (EBS) and is used as 
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an indirect measure of transcriptional activity.  HCT-116 cancer cells were co-transfected as 
indicated in Figure B.2A and treated with resveratrol (50 μM) for 24 h.  As shown in Figure 
B.2A, resveratrol increased the luciferase activity of pEBS1
4
luc-transfected cells in the 
presence of endogenous and exogenous Egr-1 levels (pBABE).  Moreover, SIRT1 
overexpression had no effect on resveratrol-induced pEBS14luc activity.  A similar effect 
was observed with pEgr-1 -1260/+35 reporter construct (Figure B.2B).  Taken together, 
these results suggest that (1) resveratrol decreases SIRT1 phosphorylation, presumably 
resulting in suppression of SIRT1 deacetylase activity, and (2) resveratrol increases Egr-1 
transcriptional activity independent of SIRT1 activation.          
 
4.3.2. Egr-1 aDaa Mutation Diminishes Resveratrol-Induced Egr-1 Activity 
 Acetylation of Egr-1 is reported to result in the preferential activation of Egr-1 pro-
survival target genes in prostate cancer 
(219)
; Egr-1 is suggested to behave as an oncogene in 
these cancers.  However, in our model system, Egr-1 facilitates the anticancer activities of 
resveratrol 
(215)
; therefore, we hypothesize that acetylation of Egr-1, through inhibition of 
SIRT1 deacetylase activity (Figure B.1), may be required for observed resveratrol-induced 
expression mediated by the transcription factor.  To test this hypothesis, we first generated an 
acetylation deficient Egr-1 construct as described in Chapter 2 based upon the identified 
putative acetylation site (KDKK) within Egr-1’s weak transactivation domain (see Figure 
B.3 for amino acid sequence 
(219)
).  
 We next determined whether resveratrol increased Egr-1 acetylation and whether it 
occurred at the KDKK site.  HCT-116 cells were transiently transfected with either control or 
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Egr-1 (WT and acetylation deficient, aDaa) constructs.  Culture of transfected cells with 
resveratrol (50 μM) for 2 h resulted in increased acetylation of both endogenous and 
exogenous Egr-1 as demonstrated using an anti-acetylated lysine antibody (Figure B.4A).  
However, Egr-1 acetylation by resveratrol was not observed in the acetylation deficient Egr-1 
aDaa construct (Figure B.4A).  Furthermore, resveratrol-induced Egr-1 transcriptional 
activity was diminished in the presence of the acetylation deficient construct (Figure B.4B).  
These results suggest that resveratrol acetylates Egr-1 and that this posttranslational 
modification, at least partially, is important in resveratrol-induced Egr-1 transcriptional 
activity.        
 
4.3.3. Acetylation Contributes to Activation of the Egr-1 Target Gene, NAG-1  
 As previously described, Egr-1 acetylation status is associated with preferential 
transactivation of either survival-related (acetylated) or apoptosis-related (unacetylated) Egr-
1 gene targets in prostate cancers 
(219)
; yet, in colorectal cancer, acetylation of Egr-1 may 
facilitate anti-proliferative and/or pro-apoptotic gene activation.  We therefore studied three 
known Egr-1 target genes to determine whether acetylated Egr-1 produced a different result 
compared to unacetylated Egr-1.  An expression study was performed in resveratrol-treated 
HCT-116 cancer cells by measuring protein (Figure B.5A) and mRNA (Figure B.5B) levels 
of activating transcription factor 3 (ATF3), NSAID-activated gene-1 (NAG-1), and p53 after 
transfection with Egr-1 WT or Egr-1 aDaa.  Figure B.5A shows that resveratrol strongly 
induced the expression of the Egr-1 target genes examined (lanes 2, 6, and 10).  Similar 
results were observed in the presence of Egr-1 WT overexpression (lanes 5 and 6).  
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However, Egr-1 aDaa was only less active in inducing NAG-1 expression when compared to 
WT in vehicle- and resveratrol-treated HCT-116 cancer cells (Figure B.5A, lanes 5 and 6 vs. 
lanes 9 and 10).  Decreased Egr-1 aDaa induced NAG-1 mRNA expression was also 
observed in control- and resveratrol-treated HCT-116 cancer cells (Figure B.5B).   
 Acetylation of non-histone proteins is suggested to alter the DNA binding affinity of 
transcription factors for their target gene 
(220)
.  Because resveratrol treatment increases Egr-1 
acetylation and subsequent expression of the Egr-1 target gene NAG-1, we sought to 
determine if this increased expression was due to increased Egr-1 binding affinity to the 
NAG-1 promoter resulting in its transcriptional activation by Egr-1.  We performed a 
chromatin immunoprecipitation (ChIP) assay to examine whether unacetylated Egr-1 (Egr-1 
aDaa) had less affinity for the NAG-1 promoter as compared to acetylated Egr-1 (Egr-1 WT).  
As shown in Figure B.6A, immunoprecipitation of chromatin/protein complex with Egr-1 
resulted in the visualization of a 202-bp band of the amplified NAG-1 promoter.  
Interestingly, in Egr-1 aDaa-transfected HCT-116 cancer cells had less promoter binding as 
compared to Egr-1 WT-transfected cells for both vehicle- and resveratrol-treated cells.  The 
observed decrease in Egr-1 aDaa binding affinity for the NAG-1 promoter also resulted in 
reduced Egr-1 induced transcriptional activation (Figure B.6B).  Taken together, these 
results suggest that Egr-1 acetylation, at least partially, contributes to Egr-1-induced NAG-1 
expression and to resveratrol-induced Egr-1-mediated NAG-1 expression in our model 
system.     
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4.4. Discussion  
The dietary phytochemical resveratrol has elicited much attention as a putative 
anticancer agent; current research demonstrates resveratrol-mediated inhibition of 
carcinogenesis and modulation of cancer-associated signal transduction pathways 
(6)
.  Yet, 
despite the identification of molecular targets, the underlying mechanisms that mediate 
resveratrol’s anticancer activities remain elusive, especially in colorectal cancer.  In this 
present study, we sought to investigate the role of SIRT1 in resveratrol-induced Egr-1 
transcriptional activity.  Our data revealed a SIRT1-independent mechanism for resveratrol-
induced Egr-1 activity and suggest the importance of acetylation, at least partially, in this 
response.   
Recently, it has been suggested that SIRT1 contributes to the anticancer activity(s) of 
resveratrol; the authors of that study demonstrate reduced resveratrol-mediated tumor 
inhibition (incidence, load, and volume) in SIRT1-null mice as compared to normal using a 
two-stage model of skin carcinogenesis 
(214)
.  Similarly, Wang et al. 
(213)
 showed that 
activation of SIRT1 by resveratrol could partially inhibit tumor formation attributable to 
delayed tumor onset.  Moreover, the tumors that developed in resveratrol-treated mice did 
not contain SIRT1, thus explaining why resveratrol did not inhibit tumor formation is this 
group 
(213)
.  Based on these studies, one could infer that the inhibitory effect of resveratrol on 
carcinogenesis is predicated on SIRT1 activity.  Yet, as we demonstrate here, enhanced Egr-1 
transcriptional activity by resveratrol occurs in a SIRT1-independent manner (Figure B.1. 
and B.2).  This contradicts the notion of a SIRT1-dependent component to the anticancer 
effects of resveratrol.  Recent evidence; however, suggests that resveratrol is not a direct 
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activator of SIRT1 
(221)
 and resveratrol inhibition of tumor growth is SIRT1-independent 
(222)
.  
The results presented here are in agreement with these latest findings.   
Acetylation of non-histone proteins at lysine residues is suggested to modulate 
protein function (e.g. signal transduction, DNA binding, protein stability, and localization) 
(220)
.  Furthermore, as in the case of the tumor suppressor p53, acetylation of transcription 
factors at lysine residues by the p300/CBP acetyltransferase may increase DNA binding 
affinity followed by subsequent transcriptional activation of their target genes 
(223)
.  
Therefore, inhibition of SIRT1 deacetylase activity by resveratrol may contribute to Egr-1 
acetylation and increased Egr-1 transcriptional activity.  Indeed, our results suggest that 
resveratrol-induced Egr-1 activity is associated with the transcription factor’s acetylation 
(Figure B.4).  However, the acetyltransferase responsible for Egr-1 acetylation remains to be 
identified, although p300/CBP involvement is likely 
(219)
.   
Egr-1 belongs to a family of immediate early response genes whose expression is 
transiently induced in response to various environmental stimuli 
(185)
 and is suggested to act 
as a master regulatory protein involved in cell fate decisions 
(189)
.  Several reports indicate 
Egr-1 involvement in the activation of the pro-apoptotic proteins ATF3 
(155, 156, 215, 224)
, NAG-
1 
(225-229)
, and p53 
(228, 230, 231)
.  Additionally, Yu et al. 
(219)
 reported that acetylation of Egr-1 at 
the KDKK motif, within its weak transactivation domain, dictated its role in cell fate 
decisions in prostate carcinogenesis.  Thus, to determine if Egr-1 acetylation status is 
associated with Egr-1 mediated cell fate decisions in our HCT-116 colorectal cancer cell 
model, we examined the expression of these three Egr-1 targets.  As shown in Figure B.5, 
we observed less NAG-1 expression for acetylation deficient Egr-1 aDaa construct-
 
 71 
transfected HCT-116 colorectal cancer cells as compared to Egr-1 WT-transfected cells.  
Decreased NAG-1 expression by the acetylation deficient Egr-1 occurred, presumably, 
through decreased NAG-1 promoter binding followed by diminished NAG-1 transactivation 
(Figure B.6).  However, expression of Egr-1 aDaa had no appreciable effect on ATF3 or p53 
expression; this observation may be due to the involvement of other transcription factors in 
resveratrol-mediated ATF3 or p53 activation. 
In conclusion, we demonstrate here a SIRT1-independent mechanism for increased 
Egr-1 transcriptional activity by resveratrol, associated with the inhibition of SIRT1 
deacetylase activity (Figure 4.1).  The study also demonstrates the importance of acetylation 
in resveratrol-induced Egr-1 activity.  Acetylation facilitates Egr-1-induced NAG-1 
expression through increased Egr-1 binding to the NAG-1 promoter followed by enhanced 
transactivation in the presence of resveratrol.  Thus, acetylation of Egr-1 plays an important 
role in resveratrol-mediated transactivation of NAG-1.    
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Figure 4.1. Schematic diagram of the role of resveratrol-induced Egr-1 acetylation in colon 
cancer cells.   In colorectal cancer, resveratrol increases Egr-1 acetylation through a yet to be 
identified acetyltransferase, resulting in increased NAG-1 expression and subsequent induction of 
anticancer effects such as apoptosis.     
 
 73 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: 
 
Conclusions and Future Perspectives 
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 The continued identification of dietary phytochemicals and their related derivatives 
with chemopreventive and/or chemotherapeutic activities offers an alternative and 
complementary approach to the prevention and treatment of cancers.  Studies investigating 
the use of these compounds for cancer prevention or as adjuvants to traditional therapies have 
revealed several potential benefits: (1) suppression of tumorigenesis and carcinogenesis in 
vitro and in vivo, (2) sensitization of cancer cells to drug-induced growth inhibition, and (3) 
minimization of adverse effects associated with conventional therapies.  Most importantly, 
dietary phytochemicals are demonstrated to target multiple signal transduction pathways 
involved in cancer development, an important advantage due to the inherent heterogeneity of 
cancers. 
 Resveratrol (3, 4’, 5-trihydroxystilbene), a naturally-occurring phytoalexin, has been 
identified in extracts from more than 70 plant species, including grapes (predominant 
source), berries, jackfruit, and peanuts 
(232)
.  Since Jang et al. 
(5)
 first identified the inhibitory 
effect of resveratrol on carcinogenesis, numerous studies have demonstrated the capacity of 
resveratrol to modulate a multitude of signaling pathways associated with cancer 
development (see Chapter 1).  As a result, we postulate that resveratrol may function as a 
potential signaling pathway modulator and it is likely that this collective activity, rather than 
just a single effect, plays an important role in the anticancer properties of resveratrol.   
 However, despite the identification of numerous molecular targets, the underlying 
mechanisms involved in the antitumor/anticancer activities of resveratrol, especially in 
colorectal cancer, are complex and remain poorly defined.  Thus, we sought to investigate the 
effect of resveratrol on gene modulation in human colorectal cancer cells in order to identify 
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and characterize novel molecular targets that may contribute to observed antitumor activities 
of resveratrol.  The data presented in Chapter 3 and in Chapter 4 suggest that activating 
transcription factor 3 (ATF3) and early growth response-1 (Egr-1), respectively, are novel 
molecular targets of resveratrol in colorectal carcinogenesis.   
 ATF3, a stress-inducible or adaptive response gene, is suggested to function as a 
tumor suppressor gene in colorectal carcinogenesis due to its inhibitory effects on tumor cell 
proliferation, tumor formation, and invasion (see Chapter 3 for references).  Here, we 
identify ATF3 as a target of resveratrol that contributes to apoptosis induced by the dietary 
phytoalexin in vitro.  Furthermore, resveratrol-increased ATF3 expression is mediated 
through Egr-1 and Krüppel-like factor 4 (KLF4) interactions, which occurs via the activation 
or zinc-finger domain of Egr-1.  These findings show, for the first time, the involvement of 
resveratrol in the transcriptional regulation of ATF3, mediated by Egr-1 and KLF4, and that 
increased ATF3 expression facilitates induction of apoptosis by resveratrol.   
 Egr-1, characterized as an immediate early response transcription factor, is also 
suggested to behave as a tumor suppressor in colorectal cancer (refer to Chapter 3 and 
Chapter 4).  The data presented in Chapter 4 suggest that increased Egr-1 transcriptional 
activity by resveratrol is dependent on the resveratrol-induced posttranslational acetylation of 
Egr-1, which is SIRT1-independent in vitro.  Thus, resveratrol not only affects Egr-1 at the 
level of transcription (Chapter 3), but affects Egr-1 at the level of translation as well.  Egr-1 
acetylation by resveratrol contributes, at least partially, to Egr-1 induced expression of the 
pro-apoptotic protein NAG-1.  Again, these findings represent a novel mechanism by which 
resveratrol induces Egr-1 transcriptional activity that is independent of SIRT1 expression.   
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 Yet, in order to identify ATF3 or Egr-1 (and even KLF4) as genuine targets of 
resveratrol, we must validate the importance of these proteins in the anticancer activity of 
resveratrol in vivo.  This can be readily achieved using an azoxymethane-induced model of 
colorectal carcinogenesis with ATF3-null 
(233)
 and Egr-1-null 
(234)
 mice.  With this model we 
can examine the involvement of ATF3 and Egr-1 in resveratrol-mediated chemoprevention 
(administration of resveratrol prior to azoxymethane injection) and chemotherapy 
(azoxymethane injection prior to resveratrol administration).  It would also be interesting to 
examine the role of ATF3 and Egr-1 using APC
min/+ 
mice, a genetic model that results in 
adenoma formation in the small intestine. 
 Therefore, in addition to the classical approaches to chemotherapy, the role of 
resveratrol as an adjuvant therapy to standard cancer treatments should be evaluated.  As 
discussed, resveratrol is demonstrated to potentiate the cytotoxic effects of known 
chemotherapeutic drugs and could alleviate associated adverse effects.  Most patients would 
readily accept the addition of a low toxicity agent such as resveratrol as adjuvants to 
chemotherapy.  Additionally, the molecular targets described in Chapter 1 should be 
evaluated in an adjuvant setting to determine its contributions to the anticancer benefits of 
resveratrol; validation of such targets could identify novel therapeutic targets for the 
treatment of cancer and justify the use of resveratrol as an anticancer drug.  Moreover, the 
identification of the novel molecular targets ATF3 (Chapter 3) and Egr-1 (Chapter 4), and 
subsequent validation as a target in vivo, provide an additional explanation of how resveratrol 
exerts its anti-tumorigenic and anti-carcinogenic effects in colorectal cancer.               
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Figure A.1. Effect of resveratrol on gene expression in HCT-116 cells.  (A) HCT-116 cells were 
treated with vehicle or resveratrol (Resv) in serum-free media for 24 h.  RT-PCR was performed 
using specified human primers as described in Chapter 2.  GAPDH served as a loading control.  
Representative gel pictures of three independent experiments are shown.  (B) Gel densitometry results 
from three experiments for the respective genes in (A).  Values are expressed as fold induction 
relative to vehicle-treated cells adjusted to GAPDH.  Statistical significance is shown as p < 0.05* 
and p < 0.01**. 
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Figure A.2. Resveratrol increased ATF3 expression in cancer cells.  Cancer cells were seeded and 
grown to 60% to 80% confluence, serum starved overnight, and treated with Resv as indicated in 
serum-free media.  Protein lysates were harvested and subjected to Western blot analysis using ATF3 
and Actin antibodies.  (A) HCT-116 cells were treated with 0, 10, 50, and 100 μM Resv for 24 h.  (B) 
HCT-116 cells were incubated with Resv (50 μM) for the indicated times.  (C) Colorectal (HT29, 
Caco-2, LoVo, and SW480) and (D) non-colorectal (NCI-H292 lung, MCF7 breast, PC3 prostate, and 
SqCC/Y1 head and neck) cancer cells were treated with vehicle or Resv (50 μM) for 24 h. 
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Figure A.3. Resveratrol response element located within the -514 to +34 bp region of the ATF3 
promoter.  (A) Each indicated construct of the ATF3 promoter (0.5 μg) and pRL-null (0.05 μg) were 
transiently transfected into HCT-116 cells and treated with vehicle or Resv (50 μM) for 24 h.  The 
promoter activity was measured as a ratio of firefly luciferase signal/renilla luciferase signal.  The x-
axis shows relative luciferase unit of each construct.  The results are the mean  SD of 3 replicates.  
 p < 0.05*; p < 0.01**; and p < 0.001***, on the basis of Student’s t test.  (B) Nucleotide sequence 
of the -514 to +34 bp region of the ATF3 promoter.  Predicted binding sites of identified transcription 
factors are capitalized and underlined with name located underneath.   
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Figure A.4. Egr-1 and KLF4 contribute to resveratrol-induced ATF3 expression.  Empty vector 
(pcDNA3.1/NEO, EV) or the indicated expression vector (0.25 μg each) was co-transfected with 
pATF3-514/+34 (A), pATF3-132/+34 (B), or pATF3-84/+34 (C) and pRL-null vector (0.05 μg) into 
HCT-116 cells.  Cells were then treated with vehicle or Resv (50 μM) in serum-free media for 24 h.  
The x-axis shows fold induction relative to EV control.  Data analyzed using Tukey’s multiple 
comparison tests.  Means with same letters indicate no significance (p < 0.05).  
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Figure A.5. Both Egr-1 and KLF4 are involved in resveratrol induction of ATF3.  (A) pATF3-
514/+34 or its internal deletion clones (0.5 μg) were transfected into HCT-116 cells followed by 
treatment with vehicle or Resv (50 μM) in serum-free media for 24 h.  Values were normalized to 
vehicle treatment.  The x-axis represents fold induction relative to the pATF3-514/+34 control.  Data 
analyzed using Tukey’s multiple comparison test; mean values with the same letters indicate no 
significance (p < 0.05).  (B) HCT-116 cells were transfected with Egr-1 sense/antisense 
oligonucleotides or control/KLF4 siRNA using TransIT-TKO transfection reagent.  Cells were serum 
starved overnight and treated with vehicle or Resv (50 μM) for 6 h (KLF4) or 24 h (Egr-1).  Protein 
lysates were harvested and subjected to Western blot analysis for Egr-1 or KLF4, ATF3, and Actin. 
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Figure A.6. Egr-1 and KLF4 bind to the ATF3 promoter, EMSA.  Gel shift assays were 
performed using nuclear extracts (NE) from Resv (50 μM)-treated HCT-116 cells for 24 h or in vitro 
translated (IVT) proteins as described in Chapter 2.  Competitions were done in the presence of 10X 
and 100X excess of unlabeled oligonucleotides (lanes 3-4 and 10-11).  Specificity of the DNA/protein 
complex was confirmed by the absence of competition with an excess of unlabeled mutated 
oligonucleotide (lanes 5-6 and 12-13).  A, Egr-1 and B, KLF4.  Arrows, DNA/protein complexes. 
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Figure A.7. Egr-1 and KLF4 bind to the ATF3 promoter, ChIP.  HCT-116 cells were treated with 
vehicle or Resv (50 μM) for 24 h.  The chromatin/protein complexes were cross-linked by 
formaldehyde treatment, and chromatin pellets were extracted and sonicated.  The associated Egr-1 
and KLF4 DNA was isolated as described in Chapter 2.  The sequence of the human ATF3 promoter 
(-298/-114) was amplified by PCR primer pairs (arrows).  The input represents PCR products 
obtained from 1% aliquots of chromatin pellets before immunoprecipitation.  Left, ChIP qRT-PCR.  
The x-axis shows enrichment relative to input.  The results are the mean  SD of three independent 
experiments.  Right, RT-PCR; representative gel picture of three experiments is shown. 
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Figure A.8. de novo protein synthesis of Egr-1 and KLF4 is necessary for resveratrol-mediated 
ATF3 activation.  (A) HCT-116 cells were pretreated with cycloheximide (CHX, 10 mg/mL) for 30 
min in serum-free media followed by treatment with Resv (50 μM) for 24 h.  Values are normalized 
fold induction relative to GAPDH expression.  The data are representative of three independent 
experiments.  (B) HCT-116 cells were treated with vehicle or Resv (50 μM) in serum-free media for 
24 h.  RT-PCR was performed using Egr-1, KLF4, and GADPH human primers; the latter served as a 
loading control.  Representative gel pictures (top) and gel densitometry (bottom) of three independent 
experiments are shown.  Values are expressed as fold induction relative to vehicle-treated cells 
adjusted to GAPDH.  p< 0.05* and p< 0.01**, based on Student’s t test.  (C) HCT-116 cells were 
serum starved overnight and treated with Resv (50 μM) for the indicated times.  Protein lysates were 
harvested and subjected to Western blot analysis using ATF3, Egr-1, KLF4, and Actin antibodies. 
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Figure A.9. Egr-1 and KLF4 coordinate the expression of resveratrol-induced ATF3 expression.  
The pATF3-514/+34 reporter construct (0.25 μg) was co-transfected with pcDNA3.1 (empty), Egr-1, 
and KLF4 expression vectors as indicated in the presence of pRL-null vector (0.05 μg).  Cells were 
treated with vehicle or Resv (50 μM) in serum-free media for 24 h.  The y-axis shows fold induction 
relative to pcDNA3.1 control.  The results are the mean  SD of three replicates.  Data analyzed using 
Tukey’s multiple comparison test; mean values with the same letters indicate no significance (p < 
0.05). 
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Figure A.10. Increased Egr-1 and KLF4 interact after resveratrol treatment.  Mammalian 2-
hyrid assay was performed as described in Chapter 2.  (A) HCT-116 cells were co-transfected with 
pM and pVP16 vectors or pM/Egr-1 and pVP16/KLF4 vectors (0.2 μg each) in the presence of 
pG5luc vector (0.2 μg) and pRL-null vector (0.06 μg).  Cells were treated with vehicle, Resv (50 μM), 
or DIM (25 μM) for 24 h in serum-free media.  Promoter activity was measured as a ratio of firefly 
luciferase/renilla luciferase signal, and the results are expressed as the mean  SD of three 
independent experiments.  The y-axis shows fold induction over control vectors.  Data analyzed using 
Tukey’s multiple comparison test; mean values with the same letters indicate no significance (p < 
0.05).  (B) Top, schematic diagram of Egr-1 protein structure and locations used to generate internal 
deletions.  Bottom, HCT-116 cells were transfected with pM/Egr-1 internal deletion constructs, 
pVP16/KLF4 vector, and pG5luc vector.  Cells were treated with vehicle or Resv (50 μM) in serum-
free media for 24 h.  Values are normalized to vehicle treatment.  The y-axis represents fold induction 
relative to pM/Egr-1 and pVP16/KLF4 control.  Data analyzed using Tukey’s multiple comparison 
test; mean values with the same letters indicate no significance (p < 0.05).  
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Figure A.11. Confirmation of Egr-1 and KLF4 interaction in the presence of resveratrol.  HCT-
116 cells were transfected with empty (EV), Egr-1 (WT or deletion), or co-transfected with KLF4 
expression vectors as indicated and grown to 80% confluence.  Cells were serum starved overnight, 
treated with Resv (50 μM) for 2 h, and harvested as described in Chapter 2.  Cell extracts were 
immunoprecipitated and immunoblotted with antibody against Egr-1 or KLF4.  
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Figure A.12. Relevance of ATF3 in resveratrol-induced apoptosis.  Caspase 3/7 enzymatic 
activity was measured as described in Chapter 2.  (A) HCT-116 and HT29 cells were treated with 0, 
10, 50, and 100 μM Resv for 24 h.  Data analyzed using Tukey’s multiple comparison test; mean 
values with the same letter indicate no significance (p < 0.05).  (B) HCT-116 and HT29 cells were 
transfected with empty or ATF3 expression vector and grown to 60% to 80% confluence.  Cells were 
serum starved overnight and treated with the pan caspase inhibitor z-vad-fmk (ZVF, 1 μM) for 3 h.  
ATF3 overexpression was validated (top).  (C) HCT-116 cells were transfected with control/ATF3 
siRNA using TransIT-TKO transfection reagent and treated with Resv (50 μM) for 24 h.  ATF3 
knockdown was validated (left).  p < 0.01** and p < 0.001***, on the basis of Student’s t test. 
  
 
 111 
 
Figure A.13. Egr-1 and KLF4 activate ATF3 independent of resveratrol.  Empty vector or the 
indicated expression vector (0.25 μg each) was co-transfected with the ATF3 promoter construct in 
the presence of pRL-null vector (0.05 μg) into HCT-116 cells.  Promoter activity was measured as a 
ratio of firefly luciferase signal/renilla luciferase signal.  The x-axis shows fold induction relative to 
pcDNA3.1 control.  The results are the means ± SD of three replicates. A, Egr-1 and B, KLF4.   
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A.14. Posttranscriptional regulation of ATF3 as an alternate regulatory pathway.  HCT-116 
cells were incubated with vehicle or Resv (50 μM) for 24 h and subsequently treated with 
antinomycin D (Act D, 5 μM).  At the indicated times, total RNA was isolated, and RT-PCR was 
performed using ATF3 and GAPDH human specific primers, the latter served as a loading control.  
Representative gel pictures (top) and gel densitometry (bottom) of three independent experiments are 
shown.  Values are expressed as percentage of relative ATF3 transcript present at Time 0 of Act D 
treatment.  
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Figure B.1.  Resveratrol decreases serine 27 SIRT1 phosphorylation.  HCT-116 cells were seeded 
and grown to 60% to 80% confluence, serum starved overnight, and treated with Resv as indicated in 
serum-free media.  Protein lysates were harvested and subjected to Western blot analysis using 
pSIRT1 (Ser 27), pSIRT1 (Ser 47), SIRT1, and Actin antibodies.   
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Figure B.2. Increased Egr-1 activity by resveratrol is SIRT1-independent.  (A) HCT-116 cells 
were co-transfected with EV and pEBS1
4
luc vectors (0.25 μg each) or Egr-1 and pEBS1
4
luc vectors 
(0.25 g each) in the presence of SIRT1 expression vector (0.25 μg) and pRL-null vector (0.0075 μg).  
Cells were treated with vehicle or Resv (50 μM) for 24 h in serum-free media.  (B) pBABE or SIRT1 
(0.375 μg) was co-transfected with pEgr-1 -1260/+35 (0.375 μg) or pRL-null vector (0.0075 μg) into 
HCT-116 cells and treated with vehicle or Resv (50 μM) in serum-free media for 24 h.  Promoter 
activity for (A) and (B) was measured as a ratio of firefly luciferase signal/renilla luciferase signal, 
and the results are expressed as the mean ± SD of 3 replicates.  The y-axis shows fold induction over 
vehicle control.   
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Figure B.3. Egr-1 amino acid sequence and predicted acetylation site.   
 
 
 
 
 
 
Figure B.4. Egr-1 aDaa mutation diminishes resveratrol-induced Egr-1 activity.  (A) HCT-116 
cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa vectors and grown to 80% confluence. 
Cells were serum starved overnight, treated with Resv (50 μM) for 2 h, and harvested as described in 
Chapter 2.  The cell extracts were immunoprecipiated with Egr-1 and immunoblotted with antibody 
against Egr-1 and acetylated lysine.  (B) EV, Egr-1, or Egr-1 aDaa expression vector (0.375 μg each) 
was co-transfected with pEBS1
4
luc (0.375 μg) and pRL-null vector (0.0075 μg) into HCT-116 cells.  
Cells were then treated with vehicle or Resv (50 μM) in serum-free media for 24 h.  The promoter 
activity was measured as a ratio of firefly luciferase signal/renilla luciferase signal.  The y-axis shows 
fold change relative to vehicle control.  The results are the mean ± SD of 3 replicates.  Data analyzed 
using Tukey’s multiple comparison test; mean values with same letters indicate no significance (P < 
0.05). 
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Figure B.5. Acetylation contributes to activation of the Egr-1 target gene, NAG-1.  HCT-116 
cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa and grown to 80% confluence.  (A) Cells 
were serum starved overnight and pre-treated with Resv (50 μM) for 2 h followed by TSA (1 μM) for 
24 h as indicated.  Protein lysates were harvested and subjected to Western blot analysis using ATF3, 
NAG-1, p53, Egr-1, and Actin antibodies.  (B) qRT-PCR was performed as described in Chapter 2 
for NAG-1.  Values are normalized to fold induction relative to GAPDH expression.  The data are 
representative of 3 independent experiments.   
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Figure B.6. Acetylation contributes to NAG-1 promoter binding and transactivation by Egr-1.  
HCT-116 cells were transfected with EV, Egr-1 WT, or Egr-1 aDaa vectors and grown to 80% 
confluence.  (A) The sequence of the human NAG-1 promoter (-133/+31) was amplified by PCR 
primer pairs.  The input represents PCR products obtained from 1% aliquots of chromatin pellets 
before immunoprecipitation.  Representative gel picture of three experiments is shown.  (B) Each 
vector (0.375 μg) was co-transfected with pNAG-1 -133/+41 (0.375 μg) or pRL-null vector (0.0075 
μg) into HCT-116 cells and treated with vehicle or Resv (50 μM) in serum-free media for 24 h.  
Promoter activity for was measured as a ratio of firefly luciferase signal/renilla luciferase signal, and 
the results are expressed as the mean ± SD of 3 replicates.  The y-axis shows fold induction over 
vehicle control.  p < 0.001***, on the basis of Student’s t test.   
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